Embed Size (px)
Citation preview
O'Connor, Daniel T.
1 1
2-26-2007 CURRICULUM VITAE
Daniel Thomas O'Connor, Jr., M.D.
ADDRESS:
Division of Nephrology-Hypertension (0838) Department of Medicine and Center for Human Genetics and Genomics University of California at San Diego (UCSD) School of Medicine & VASDHS Skaggs (SSPPS) room 4256 9500 Gilman Drive La Jolla, CA 92093-0838 USA Tel (858)-534-0661 Fax (858)-534-0626 E-mail: [email protected] Internet: http://medicine.ucsd.edu/hypertension http://elcapitan.ucsd.edu/hyper Map <http://maps.ucsd.edu> building #783 EDUCATION: High School: Loyola High School, Los Angeles, CA Graduated 1966, classical diploma College: Loyola University, Los Angeles, CA B.S. degree, Biology, 1970 Medical School: University of California at Davis, School of Medicine, Davis, CA M.D. degree, 1974 HONORS/AWARDS: National Merit Scholarship finalist 1966 President's Scholar, University of California 1970-1 Alpha Omega Alpha (elected) 1973 Upjohn Achievement Award for Outstanding Clinical 1974 Proficiency, UC Davis School of Medicine Senior Class Award, UC Davis School of Medicine (elected) 1974 Associate Investigator, Medical Research Service, 1977-9 Veterans Administration Young Investigator Award, National Heart, Lung & Blood 1979 Institute (declined, to accept Research Assoc. Award) Research Associate, Medical Research Service, 1980-3 Veterans Administration Established Investigator Award, American Heart Association 1983-8 Western Society for Clinical Investigation (elected) 1983 Fellow, American Heart Association Council for High Blood 1983 Pressure Research (elected)
O'Connor, Daniel T.
2
Harry Goldblatt Award for Cardiovascular Research, American 1985 Heart Association Council for High Blood Pressure Research American Society for Clinical Investigation (elected) 1986 Western Association of Physicians (elected) 1986 United States Patent #4,758,522: "Immunoassay of Human 1988 Chromogranin A" (19 claims allowed) Young Scholar Award, American Society of Hypertension 1989
Distinguished Alumnus Award, UC Davis School of Medicine 1989 Clinical Investigator, Dept. of Veterans Affairs 1989-94 Associate Editor, Journal of Clinical Investigation 1992-94 Association of American Physicians (elected) 1995 International Symposia for Chromaffin Cell Biology (ISCCB) International Advisory Board 1995-present Chair, local organizing committee, ISCCB-11, San Diego 1999-2001 UCSD School of Medicine Faculty Distinguished Lecturer 1998 UCSD Department of Medicine PRISM lecturer 2003 (Progress in the Science of Medicine) POSTGRADUATE EXPERIENCE: Intern and resident, Internal Medicine, Dept. of Medicine, UCSD 1974-1977 Clinical fellow, Nephrology/Hypertension, Dept. of Medicine, UCSD 1976-1977 Postdoctoral/reserch fellow, Nephrology/Hypertension, UCSD 1977-1978 Sabbatical, molecular biology, UCSD 1986-1987 UNIVERSITY (UCSD) APPOINTMENTS: Department of Medicine, Division of Nephrology/Hypertension, UCSD Instructor 1978-1979 Assistant Professor of Medicine 1979-1985 Associate Professor of Medicine 1985-1991 Professor of Medicine 1991-present Director, Hypertension, UCSD 1994-present Department of Pharmacology, UCSD Adjunct Professor of Pharmacology 2004-present Member, UCSD Center for Molecular Genetics 1987-present Director, UCSD/NIH “Autonomic Pharmacodynamic Pharmacogenomics” Ctr. 2001-5 Co-Director, UCSD Center for Human Genetics and Genomics 2004-present HOSPITAL APPOINTMENTS: Staff Nephrologist, San Diego VA Medical Center 1979-present Attending Staff Physician, UCSD Medical Center 1978-present Chief, Hypertension, San Diego VA Medical Center 1983-2004 Acting Chief, Nephrology-Hypertension, San Diego VA Medical Center 1988-1989 LICENSURE AND CERTIFICATION: National Board of Medical Examiners 1976 Licensure, Board of Medical Examiners, State of California 1976 Diplomate, American Board of Internal Medicine 1977 Diplomate, American Board of Internal Medicine, 1980 Subspecialty in Nephrology/Hypertension American Society of Hypertension, Specialist in Clinical Hypertension 1999 SOCIETIES AND ORGANIZATIONS:
O'Connor, Daniel T.
3 3
Alpha Omega Alpha (elected, 1973) American Federation for Clinical Research (Western Section Councillor from UC San Diego School of Medicine, 1984-1987) American Society of Nephrology American Society of Hypertension (charter member). ASH Specialist in Clinical Hypertension (1999-2009) Western Society for Clinical Investigation (elected, 1983) American Society for Clinical Investigation (elected, 1986) Western Association of Physicians (elected, 1987) Association of American Physicians (elected, 1995) American Physiological Society American Society for Biochemistry and Molecular Biology American Association for the Advancement of Science
American Heart Association: Member, Council on High Blood Pressure Research Fellow, Council on High Blood Pressure Research (elected, 1983) Member, Publications Committee, Council on High Blood Pressure Research (1986-1987) Member, Kidney Council National Kidney Foundation of Southern California Member, Research Committee: 1981; 1985-1986; 1990-1991. National Kidney Foundation Program Committee, National Meeting, 1995 Faculty member, Biomedical Sciences (formerly Physiology/Pharmacology) graduate program, UC San Diego School of Medicine (1984-present) Faculty member, Neuroscience graduate program, UC San Diego School of Medicine (1985-present) Member, UC San Diego Center for Molecular Genetics (1987-Present) Editorial boards: Clinical and Experimental Hypertension (1981-90) American Journal of Kidney Diseases (1985-90) Hypertension (1990-3) Journal of Clinical Investigation (1992-7)(Associate Editor, 1992-4). International Society for Chromaffin Cell Biology (ISCCB) International Advisory Board (1995-) Chair (1999-2001). RESEARCH SUPERVISION OF STUDENTS AND FELLOWS: Medical (MD) or undergraduate student independent study (senior thesis) research at UCSD. 1. Richard A. Preston, M.D. (UCSD, 1979) Prazosin and renal hemodynamics: arteriolar vasodilation during therapy of essential hypertension. 2. Eric H. Sasso, M.D. (UCSD, 1980) Prazosin depression of baroreflex function in
hypertensive man. 3. Gerald Sugino, M.D. (UCSD, 1982) Renal perfusion is preserved during cardioselective beta blockade with metoprolol in hypertension. 4. John T. Mullen, M.D. (UCSD, 1987) Effects of non-chloride salts of potassium on
blood pressure. 5. Ray J. Hsiao, M.D. (UCSD, 1989) Human chromogranin A in neuroblastoma,
pheochromocytoma, and renal disease. 6. Dat Q. Vo, M.D. (UCSD, 1991) Candidate genes in genetic hypertension.
O'Connor, Daniel T.
4
7. Huan Nguyen, M.D. (UCSD, 1991) Renal clearance studies during angiotensin converting enzyme inhibition in renal insufficiency.
8. T. Teresa Dao, M.D. (UCSD, 1995). Mendelian autonomic phenotypes in human essential hypertension.
9. Joseph A. Martinez (UCSD, 1997). Kallikrein as a candidate gene in essential hypertension.
10. Elizabeth A. Tyrell, M.D. (UCSD, 1996). Early changes in glomerular filtration in hereditary hypertension.
11. Regina A. Wu, M.D. (Loyola University, Chicago 1996). Central autonomic effects of angiotensin converting enzyme inhibitors in hypertension.
12. Lisa U. Yoneda, BS (UCSD, 1996). Positional cloning of hypertension genes in the mouse.
13. Vanita R. Aroda, MD (UCSD, 1998). A novel catecholamine release-inhibitory peptide.
14. Alexander Lee, MD (UCSD, 1999). Catecholamine release-inhibitory actions of PAMP.
15. Victoria Edmond, MD (UCSD, 1997). Hereditary hypertension. 16. Chin K. Song, MD (UCSD, 1999). Renal kallikrein excretion in ethnically and
genetically stratified populations. 17. Christopher Olonan, MD (UCSD, 2002). Novel chimeric photoproteins to
measure chromaffin granule calcium. 18. Darius Walker, BS (Clark University, 2002). Positioning human autonomic
scuceptibility loci by radiation hybrid mapping. 19. Omar Halawa, BS (UNC/Chapel Hill, 2004). Informatics in hereditary
hypertensive phenotypes. 20. Carie Nguyen, BS (UCSD, 2003). Autonomic pharmacology of sympathomimetic
amines. Graduate student (PhD) thesis research supervision at UCSD. 1. Roger L. Sokoloff, for Ph.D. in Chemistry, 1982. Undergraduate: UC Berkeley.
Soluble and membrane-bound dopamine-beta-hydroxylase from human and cow: structural comparisons (1979-82). Ph.D., UCSD, 1982.
2. Bruce M. Gill, graduate student in Biomedical Sciences. Undergraduate: UCSD. Chromogranin structure and function (1987-92). Ph.D., UCSD, 1992.
3. David J. Rozansky, graduate student (M.D./Ph.D. student) in Biomedical Sciences (1989-1993). Undergraduate: Stanford University. A glucocorticoid response element in the chromogranin A promoter. Ph.D., UCSD, 1993.
4. Hongjiang Wu, M.D., graduate student in Biomedical Sciences (1990-4). Undergraduate: Bejing Medical University, China). The chromogranin A gene: cell type-specific expression. Ph.D., UCSD, 1994.
5. Xiaobo Zhang, M.D., graduate student in Molecular Pathology (1993-4). Undergraduate: Military Medical College, China. Cell type-specific expression of chromogranin A in somatolactotropes. M.S., UCSD, 1994.
6. Carolyn V. Livsey, graduate student in Biomedical Sciences (1996-2001). Undergraduate: UC Davis. Chromogranin processing and intracellular trafficking. PhD, UCSD, 2001.
7. Surin Chitbangonsyn, M.S., graduate student, UCSD (2000-2002). Undergraduate: UCSD. Radiation hybrid library screening for hypertension candidate loci. M.S., UCSD, 2002.
8. Ryan Fries, graduate student in Bioengineering (2003-7). Undergraduate: USC. Adrenal gene expression profiling in rodent genetic hypertension.
O'Connor, Daniel T.
5 5
9. Rany Salem, MPH, graduate student in genetic epidemiology (2003-7). Undergraduate: UCSD. Functional genomics of allelic variation at the human chromogranin B locus (CHGB).
10. Juan L. Rodriguez, graduate student in Bioinformatics (2006-). Undergraduate: MIT. Statistical genetic approaches to heredity of sympathochromaffin traits.
Doctoral (PhD thesis) committees at UCSD. 1. Roger L. Sokoloff, for Ph.D. in Chemistry (chair). 2. Marshall Snavely, for Ph.D. in Physiology/Pharmacology. 3. Victoria Boyd, for Ph.D. in Physiology/Pharmacology. 4. James Moberly, for Ph.D. in Physiology/Pharmacology. 5. Ken Boheler, for Ph.D. in Physiology/Pharmacology. 6. Bruce M. Gill, for Ph.D. in Biomedical Sciences (chair). 7. Kathy Grako, for Ph.D. in Biomedical Sciences. 8. Kathy Rasmussen, for Ph.D. in Biomedical Sciences. 9. David J. Rozansky, for Ph.D. in Biomedical Sciences (chair). 10. Hongjiang Wu, for Ph.D. in Biomedical Sciences (chair). 11. Margaret Rathouz, for Ph.D. in Biology. 12. Joseph Satriano, for Ph.D. in Molecular Pathology. 13. Brian Molles, for Ph.D. in Biomedical Sciences. 14. Gina Schneider, for Ph.D. in Psychology (CSPP). 15. Allen Swei, for Ph.D. in Biomedical Engineering. 16. Camille Vogt, for PhD in Biomedical Engineering. 17. Jamie Reuter, for Ph.D. in Chemistry/Biochemistry. 18. David B. Young, for PhD in Chemistry/Biochemistry. 19. Cornelia Bentley, for PhD in Biomedical Sciences. 20. Audrey Kelleman, for PhD in Chemistry/Biochemistry. 21. Li Zhang, for PhD in Chemistry/Biochemistry. 22. Carolyn V. Livsey Taylor, for PhD in Biomedical Sciences (chair). 23. Michael Petersen, for PhD in Biomedical Sciences. 24. Sherri Liang, for PhD in Biomedical Sciences. 25. Tiffany Greenwood, for PhD in Biomedical Sciences. 26. Sandra B Moore, for PhD in Chemistry/Biochemistry. 27. John Scheel, for PhD in Biomedical Sciences. 28. David Arthur, for PhD in Biomedical Sciences. 29. Martin Jirout, for PhD in Molecular Pathology. 30. Ryan Fries, for PhD in Biomedical Engineering. 31. Rany Salem, for PhD in Genetc Epidemiology. 32. Coleman Mosley, for PhD in Bioinformatics. 33. Jennifer Wessel, for PhD in Genetic Epidemiology. 34. Minh-Ha Do, for PhD in Biomedical Sciences. 35. Edward Duc Tran, for PhD in Bioengineering. 36. Juan L. Rodriguez, for PhD in Bioinformatics. 37. Matthew Zapala, for PhD in Biomedical Sciences. Faculty on sabbatical at UCSD. 1. Guldborg Serck-Hanssen, Ph.D. (University of Oslo, Norway), 1982-1983; 1985.
University of Bergen, Norway. Chromogranin mRNA. 2. Patrick A. Sullivan, M.D. (National University of Ireland), 1986. Mallow General
Hospital, Cork, Ireland. Control of serum potassium during exercise and angiotensin converting enzyme inhibition.
O'Connor, Daniel T.
6
3. Ming-Cheng Lin, M.D. (Chung San Medical College, Taiwan), 1991-1992. Chung San Medical College, Taiwan. Intermediate phenotypes in essential hypertensive pedigrees.
4. Unni Syversen, M.D. (Oslo University, Norway), 1991. Institute of Cancer Research, Trondheim University, Norway. Purification of human chromogranin A.
5. Kazuhiro Takekoshi, MD (University of Tsukuba, Japan), 2001-2. University of Tsukuba, Ibaraki, Japan. Molecular biology of chromogranin expression in chromaffin cells.
Research/postdoctoral fellows at UCSD. 1. Sanford E. Warren, M.D. (Medical College of Virginia), 1979-1980. Renal
hemodynamic changes during longterm antihypertensive therapy. 2. Anna P. Barg, M.D. (Ohio State University), 1979-1980. Preserved renal
perfusion during treatment of essential hypertension with the beta blocker nadolol.
3. Coleman Mosely, M.D. (University of Maryland), 1981-1982. Enkephalins in rat pheochromocytoma: biochemical and physiologic studies.
4. Keevin N. Bernstein, M.D. (University of Manitoba), 1982-1983. Human catecholamine storage vesicle proteins.
5. Robert J. Parmer, M.D. (UCSD), 1982-1983; 1984-1989. Enkephalins in chromaffin tissue and in blood pressure regulation. Molecular biology of chromogranins.
6. Matthew S. Mezger, M.D. (UC Davis), 1984-1985. Radioligand binding studies on chromogranins.
7. Michiko T. Handa, M.D. (Keio University, Japan), 1986-1987. Molecular biology of chromogranins.
8. Y.-Ming Chang, M.D., 1986-1987. Radioligand binding studies on chromogranins.
9. Hongjiang Wu, M.D. (Beijing Medical University), 1987-1990. Molecular biology of dopamine-beta-hydroxylase.
10. Marwan A. Takiyyuddin, M.D. (American University of Beirut), 1987-1989. Chromaffin cell secretion. Chromogranin A synthetic peptides.
11. Juan A. Barbosa, M.D. (San Luis Potosi, Mexico), 1988-1990. Chromogranins--immunology and molecular biology.
12. John S. Videen, M.D. (University of Arizona), 1989-1991. Interactions of chromogranins with intragranular ligands.
13. Nahida L. Eskeland, Ph.D. (Mt. Sinai, NY), 1991-1994. Chromogranin A processing, and gene targeting by homologous recombination.
14. Mala T. Kailasam, M.B.B.S. (Bangalore University, India), 1992-1995. Involvement of prostaglandins in blood pressure regulation in man. Autonomic intermediate phenotypes in hypertension.
15. Dennis Cross, M.D. (Medical College of Wisconsin), 1992-1993. Intermediate phenotypes in hereditary hypertension.
16. Kechun Tang, M.D., Ph.D. (Southern Illinois University), 1992-1996. The chromogranin A promoter.
17. Sushil K. Mahata, Ph.D. (University of Calcutta, India), 1993-1995. Nicotine and reserpine response elements in the chromogranin A promoter.
18. Laurent Taupenot, Ph.D. (University of Strasbourg, France), 1995-2001. PACAP response elements in the chromogranin A promoter.
19. Caroline M. Wong, MD (Albert Einstein, NY), 1995-6. Mineralocorticoids and kallikrein.
O'Connor, Daniel T.
7 7
20. Manjula Mahata, PhD, 1996-9 (University of Calcutta, India). Function of biologically active fragments of chromogranin A.
21. Nicholas E. Preece, PhD (Surrey University, UK), 1996-9. NMR structures of chromogranin A biologically active fragments.
22. Ryuichi Fujii, M.D., Ph.D. (Kyushu University, Japan), 1997-1998. Transgenic approaches to chromogranin A.
23. Lucy M. Miller, M.D. (University of Santo Amaro Medical School, Brazil), 1997-8. Glomerular filtration in subjects at genetic risk of hypertension.
24. Melissa M. Go, M.D. (University of the Philippines), 1998-9. Adrenergic receptor polymorphisms in human hypertension.
25. Peter E. Cadman, M.D. (Columbia University), 2000-4. Actions of chromaffin granule peptides in vivo.
26. Kimberly L. Harper, M.D. (Washington University, St. Louis), 2000-2. Biologically active chromogranin/secretogranin peptides in cultured cells.
27. Clifford Wong, M.D. (UCSD), 2001-2. A novel polymorphism in the angiotensin II receptor promoter.
28. Susan Nguyen, MD (UCSD), 2002-4. RNA silencing in control of chromaffin cell gene expression.
29. Rubin Chandran, MD (Washington University, St. Louis), 2002-3. Pharmacogenetic approaches to angiotensin II blockade.
30. Fangwen Rao, MD (North Sichuan Medical College, China), 1999-2004. Hereditary auronomic phenotypes in human twins.
31. Danuta King, MD (Harvard University), 2002-4. Pharmacogenetics of presynatpic adrenergic agonist responses in a regional circulatory bed.
32. Lian Zhang, M.D. (Chongqing Medical University, China), 2002-4. Tyrosine hydroxylase polymorphisms and human autonomic function.
33. Clayton Smiley, MD (University of Chicago), 2003-4. Heritability of renal kallikrein excretion in human twins.
34. Elizabeth O. Lillie, PhD (USC, 2004), 2004-7. Twin studies of heritability in autonomic function
35. Nicholas Rowder, MD (Baylor University), 2004-6. Twin studies of uric acid metabolism.
36. Yuqing Chen, MD, PhD (Peking University), 2005-. Genomics of renal failure. 37. Kuixing Zhang, MD, PhD (Shanghai 2nd Medical University), 2005-. Genomics of
hypertension. 38. Maple Fung, M.D. (UCSD). 2006-. Heredity and cardio-renal disease risk. AWARDS WON BY TRAINEES. 1. Robert J. Parmer, M.D. (UCSD). NIH/NHLBI Physician Scientist Award, 1984-
1989. 2. Robert J. Parmer, M.D. (UCSD). Research Associate Award, Department of
Veterans Affairs, 1989-1993. 3. Robert J. Parmer, M.D. (UCSD). Henry Christian Award for Clinical Research,
American Federation for Clinical Research, 1991. 4. Hongjiang Wu, M.D. (Beijing Medical University, China). National Kidney
Foundation individual postdoctoral research fellowship, 1988-1990. 5. Keevin N. Bernstein, M.D. (University of Manitoba, Canada). National Kidney
Foundation individual postdoctoral research fellowship, 1982-1983. 6. Marwan A. Takiyyuddin, M.D. (American University, Beirut). National Kidney
Foundation / American Society of Nephrology Young Investigator Award, 1989-91 (declined, to accept NIH FIRST award).
O'Connor, Daniel T.
8
7. Marwan A Takiyyuddin, M.D. (American University, Beirut). NIH/NHLBI FIRST (First Independent Research Support After Training) Award, 1989-1994.
8. John S. Videen, M.D. (University of Arizona). NIH/NHLBI Physician Scientist Award, 1991-1996.
9. Lucy Eskeland, Ph.D. (Mt. Sinai, NY). National Kidney Foundation individual postdoctoral research fellowship, 1992-1994.
10. Bruce M. Gill, Ph.D. (UCSD). Banting and Best Fellowship, Department of Medical Research, University of Toronto, Ontario, Canada, 1992.
11. Hongjiang Wu, M.D. (Beijing Medical University). National Institutes of Health fellowship, 1993-1995.
12. Kechun Tang, M.D., Ph.D. (Southern Illinois University). National Kidney Foundation of Southern California fellowship, 1993-1994.
13. Robert J. Parmer, M.D. (UCSD). American Heart Association Established Investigator Award, 1994-1999.
14. T. Teresa Dao, M.D. (UCSD). Merck Young Investigator Award, American Heart Association Council for High Blood Pressure Research, 1994.
15. Kechun Tang, M.D., Ph.D. (Southern Illinois University). National Kidney Foundation individual postdoctoral fellowship. 1994-1996.
16. Joseph A. Martinez, MD (UCSD). American Federation for Clinical Research trainee award for outstanding abstract by a student in the Hypertension session, Western Section meeting, 1995.
17. T. Teresa Dao, M.D. (UCSD). Joseph Stokes Memorial Award, UCSD, 1995. Hamburger Medical Research Award, UCSD, 1995 (runner-up).
18. Hongjiang Wu, M.D., Ph.D. (UCSD). Merck Young Investigator Award, American Heart Association Council for High Blood Pressure Research, 1995.
19. Kechun Tang, M.D., Ph.D. (Southern Illinois University). Marion Merrell Dow fellowship award finalist, American Heart Association Council for High Blood Pressure Research, 1995.
20. Laurent Taupenot, Ph.D. (Strasbourg University, France). National Kidney Foundation of Southern California fellowship, 1995-1996.
21. Laurent Taupenot, Ph.D. (Strasbourg University, France). National Kidney Foundation individual postdoctoral fellowship, 1996-1999.
22. Laurent Taupenot, Ph.D. (Strasbourg University, France). American Heart Association, California affiliate postdoctoral Fellowship, 1996-1998. Declined, to accept NKF fellowship.
23. Victoria Edmond, MD, UCSD '97. National Medical Fellowship, 1996-1997.
24. Sushil K. Mahata, Ph.D. (University of Calcutta, India). NIH FIRST (R29) award, 1997-2002.
25. Melissa M. Go, M.D. (University of the Philippines). American Society of Hypertension/Hoechst fellowship, 1998-9.
26. Carolyn V. Livsey Taylor, PhD (UCSD). Merck Young Investigator Award. American Heart Association Council for High Blood Pressure Research, 1998.
27. Carolyn V. Livsey Taylor, PhD (UCSD). American Heart Association, Western States Affiliate, pre-doctoral fellowship, 1999-2001.
28. Peter E. Cadman, M.D. (Columbia University). American Society of Hypertension/Hoechst fellowship, 2000-1.
29. Laurent Taupenot, PhD (Strasbourg University, France). NIH K01 young investigator career development award, 2001-6.
30. Peter E. Cadman, M.D. (Columbia University). NIH K23 career development award, 2002-7.
O'Connor, Daniel T.
9 9
31. Sushil K. Mahata, Ph.D. (University of Calcutta, India). VA Merit Review grant, 2002-2005, 2005-2010.
32. Danuta King, MD (Harvard Medical School). National Kidney Foundation/AMGEN western region nephrology felllows’ research forum. First place award, 2004.
33. Sushil K. Mahata, Ph.D. (University of Calcutta, India). NIH R01 award, 2005-2010.
34. Laurent Taupenot, PhD (Strasbourg University, France). NIH PPG award, 2005-2010.
35. Elizabeth O. Lillie, Ph.D. (Universitry of Southern California). National Kidney Foundation individual postdoctoral fellowship, 2005-2007.
36. Fangwen Rao, MD (North Sichuan Medical College, China). International Society of Nephrology travel award, 2005.
37. Yuqing Chen, MD, PhD (Peking University, China). International Society of Nephrology research fellowship, 2005-6.
38. Maple Fung, MD (UCSD). National Kidney Foundation/AMGEN western region nephrology felllows’ research forum. First place award, 2007.
JOURNAL, SCIENTIFIC MEETING AND GRANTING AGENCY REVIEWER. Clinical and Experimental Hypertension (editorial board, 1981-90) Regulatory Peptides Journal of the American Medical Association Journal of Clinical Pharmacology Analytical Biochemistry Journal of Cardiovascular Pharmacology Hypertension (editorial board, 1990-1993) Archives of Internal Medicine American Journal of Kidney Diseases (editorial board, 1985-90) New England Journal of Medicine Journal of Clinical Endocrinology & Metabolism Circulation Science Journal of Histochemistry and Cytochemistry Histochemistry Journal Biochemistry Journal of Biological Chemistry Molecular Endocrinology Endocrinology Journal of Clinical Investigation (Associate Editor, 1992-1994) Veterans Administration Medical Research Service, National and Local Endocrinology study section (ad hoc), 1995-6, 2001. National Institutes of Health NHLBI site visitor, 1991. Experimental Cardiovascular Sciences (ECS) study section (ad hoc), 1997. Cardiovascular and Renal (CVB) Study Section (ad hoc), 1998-. Connaught Committee, University of Toronto National Kidney Foundation of Southern California (Research Committee, 1981; 1985-1986; 1990-1991) National Kidney Foundation program committee, national meeting, 1994-1995.
Hereditary human hypertension session organizer, 1995. American Federation for Clinical Research (Western Section) Renal/Hypertension session, 1983
O'Connor, Daniel T.
10
Hypertension/Clinical Pharmacology session coordinator, 1984 Hypertension/Clinical Pharmacology session coordinator, 1992 American Federation for Clinical Research (national meeting) Hypertension session, 1983 Hypertension session, 1991 American Society of Nephrology Hypertension session coordinator, 1983 Prostaglandin/Kinin/Renal Hormone session, 1984 Hypertension session coordinator, 1986 Hypertension session, 1988
Hypertension session, 1989 Endothelium/vasoactive hormone section, 1992. Hypertension short course organizer/chair, 1996. Intracellular protein traffic session organizer/chair, 1999. Hypertension session, 2001.
American College of Chest Physicians Hypertension session coordinator, 1988 American Society of Hypertension Endocrine/hypertension session, 1991 Endocrine/hypertension session, 1992 Clinical Hypertension Specialist Board Review question submissions, 2000. American Heart Association Cardiovascular Regulation Study Section (national), 1992. California Affiliate, Research Committee, 1991-1992 Abstract reviewer, autonomic session, 2000. Abstract reviewer, Council for High Blood Pressure Research, 2001. Council on High Blood Pressure Research, Education Committee, 2001-. Interamerican Society of Hypertension Local organizing and program committee, 1993. International Society for Chromaffin cell Biology (ISCCB), 1983-. International Advisory Board (1995-) Local Organizing Committee for 2001 meeting (chair), 1999-2001. American College of Physicians. Medical Knowledge Self Assessment Program (MKSAP),
Nephrology/Hypertension, 1996-8.
O'Connor, Daniel T.
11 11
A. PUBLISHED WORK. I. Original articles. 1976 1. Rubin RT, Poland R, O'Connor DT, Gouin P, Tower B: Selective
neuroendocrine effects of low-dose haloperidol in normal adult men. Psychopharmacol 47:135-140, 1976.
2. Gumprecht T, O'Connor DT, Rearden A, Wolf PL: Negative anion gap in a young adult with multiple myeloma. Clin Chem 22:1920-21, 1976.
1978 3. O'Connor DT, Stone RA: Hyperchloremia and negative anion gap associated
with polymixin B administration. Arch Int Med 138:478-480, 1978. 4. Warren S, O'Connor DT, Steinberg SM: Recirculation: a uremic syndrome
complicating the use of prosthetic arterio- venous fistulas for hemodialysis. J Dialysis 2:251-259, 1978.
5. O'Connor DT, Weisman MH, Fierer J: Activation of the alternate complement pathway in Staphylococcus aureus infective endocarditis and its relationship to thrombocytopenia, coagulation abnormalities and acute glomerulonephritis. Clin Exp Immunol 34:179-87, 1978.
6. Mitas JA, O'Connor DT, Stone RA: Hypertension in renal insufficiency: A major therapeutic problem. Postgrad Med 64:113-120, 1978.
1979 7. O'Connor DT, Frigon RP, Stone RA: Human pheochromocytoma dopamine
beta-hydroxylase: purification and molecular parameters of the tetrameter. Molec Pharmacol 16: 529-538, 1979.
8. Preston RA, O'Connor DT, Stone RA: Prazosin and renal hemodynamics: arteriolar vasodilation during therapy of essential hypertension. J Cardiovasc Pharmacol 1:277-286, 1979.
9. Cohen IM, O'Connor DT, Preston RA, Stone RA: Reduced renovascular resistance on clonidine. Clin Pharmacol Ther 26:572-577, 1979.
10. O'Connor DT, Preston RA, Sasso E: Renal perfusion changes during treatment of essential hypertension: prazosin vs. propranolol. J Cardiovasc Pharmacol 1(Suppl.): S38-S42, 1979.
1980 11. Warren SE, O'Connor DT: Does a renal vasodilator system mediate racial
differences in essential hypertension? Am J Med 69:425-429, 1980. 12. Warren SE, O'Connor DT: Hyperkalemia resulting from captopril administration.
J Am Med Assoc 244:2551-2552, 1980. 13. Warren SE, Viewig WVR, O'Connor DT: Sympathetic nervous system activity
during sodium restriction in essential hypertension. Clin Cardiol 3:348-351, 1980. 14. Warren SE, Cohen IM, Barg AP, O'Connor DT: Guanabenz and
hydrochlorothiazide for the treatment of essential hypertension: enhanced renal perfusion. Curr Ther Res 28: 530-534, 1980.
15. O'Connor DT, Preston RA, Sasso EH: Cambios de irrigacion renal durante al tratamiento de la hipertension arterial esencial: prazosin en comparison con propranolol. Cardiol 66(Suppl.):69-73, 1980.
16. Hsueh WA, Carlson EJ, O'Connor DT, Warren SE: Renin requires a structural alteration prior to activation by renal kallikrein. J Clin Endocrinol Metab 51:942-944, 1980.
1981
O'Connor, Daniel T.
12
17. O'Connor DT, Preston RA, Mitas JA, Frigon RP, Stone RA: Urinary kallikrein activity and renal vascular resistance in the antihypertensive response to thiazide diuretics. Hypertension 3:139-147, 1981.
18. Olshan AR, O'Connor DT, Preston RA, Frigon RP, Stone RA: Involvement of kallikrein in the antihypertensive response to furosemide in essential hypertension. J Cardiovasc Pharmacol 3:161-167, 1981.
19. Cohen IM, O'Connor DT, Preston RA, Stone RA: Long-term clonidine effects upon autonomic function in essential hypertensive man. Eur J Clin Pharmacol 19:25-32, 1981.
20. Warren SE, O'Connor DT, Cohen IM. Mitas JA: Renal hemodynamic changes during long-term antihypertensive therapy. Clin Pharmacol Ther 29:310-317, 1981.
21. Warren SE, O'Connor DT: The antihypertensive mechanism of sodium restriction. J Cardiovasc Pharmacol 3:781-790, 1981.
22. Frigon RP, O'Connor DT, Levine GL: Human dopamine beta-hydroxylase. Comparison of the enzyme from plasma, adrenal medulla, and pheochromocytoma by radioimmunoassay. Molec Pharmacol 19:444-450, 1981.
23. Schuckit MA, O'Connor DT, Duby J, Vega R, Moss M: Dopamine beta-hydroxylase activity levels in men at high risk for alcoholism, and controls. Biol Psychiatr 16:1067-1075, 1981.
24. Mitas JA, O'Connor DT, Stone RA: Evaluation of the neurogenic component of hypertension associated with dialysis and renal insufficiency. ASAIO Journal 4:56-60, 1981.
1982 25. O'Connor DT, Barg A, Duchin K: Preserved renal perfusion during treatment of
essential hypertension with the beta blocker nadolol. J Clin Pharmacol 22:187-195, 1982.
26. Sasso EH, O'Connor DT: Prazosin depression of baroreflex function in hypertensive man. Eur J Clin Pharmacol 22:7-14, 1982.
27. O'Connor DT, Frigon RP, Sokoloff RL: Human catecholamine storage vesicle proteins. Clin Exp Hypertension A4(4&5):563-575, 1982.
28. Snavely MD, Motulsky HJ, O'Connor DT, Ziegler MG, Insel P: Adrenergic receptors in human and experimental pheochromocytoma. Clin Exp Hypertension A4:829-848, 1982.
29. O'Connor DT, Preston RA: Propranolol effects upon autonomic function in hypertensive man. Clin Cardiol 5: 340-346, 1982.
30. O'Connor DT, Barg AP, Amend W, Vincenti F: Urinary kallikrein excretion after renal transplantation: relationship to hypertension, graft source and renal function. Am J Med 73: 475-481, 1982.
31. Olshan AR, O'Connor DT, Cohen IM, Mitas JA, Stone RA: Hypertension in adult onset diabetes mellitus: abnormal renal hemodynamics and endogenous vasoregulatory factors. Am J Kidney Dis 2:271-280, 1982.
32. O'Connor DT, Preston RA: Urinary kallikrein activity, renal hemodynamics and renal electrolyte handling after beta blockade with propranolol in hypertension. Hypertension 4: 742-749, 1982.
33. Morrison JH, Foote SL, O'Connor DT, Bloom FE: Laminar, tangential and regional organization of the noradrenergic innervation of monkey cortex: dopamine-beta-hydroxylase immunohistochemistry. Brain Res Bull 9:309-319, 1982.
34. O'Connor DT: Response of the renal kallikrein-kinin system, intravascular volume and renal hemodynamics to sodium restriction and diuretic treatment in essential hypertension. Hypertension 4 (Suppl. III):III72-III78, 1982.
35. Griswold W, McNeal R, O'Connor DT, Reznick V, Mendoza S: Oral converting enzyme inhibitor in malignant hypertension. Arch Dis Child 57:235-237, 1982.
1983
O'Connor, Daniel T.
13 13
36. Motulsky HJ, O'Connor DT, Insel P: Platelet alpha adrenergic receptors are normal in untreated and treated hypertensive man. Clin Sci Mol Med 64:265-272, 1983.
37. O'Connor DT, Gochman N: Lactic dehydrogenase activity in human pheochromocytoma. J Am Med Assoc 249:383-385, 1983.
38. O'Connor DT, Frigon RP, Deftos LJ: Immunoreactive calcitonin in catecholamine storage vesicles from human pheochromocytoma. J Clin Endocrinol Metab 56:582-585, 1983
39. Olshan AR, O'Connor DT, Cohen IM, Mitas JA, Stone RA: Baroreflex dysfunction in adult onset diabetics with hypertension. Am J Med 74:233-242, 1983.
40. Warren SE, O'Connor DT, Cohen IM: Autonomic and baroreflex function after captopril in hypertension. Am Heart J 105:1002-1008, 1983.
41. Gozes I, O'Connor DT, Bloom FE: Sequestration of vasoactive intestinal polypeptide in pheochromocytoma chromaffin granules: a possible high molecular weight precursor. Regulatory Peptides 6:111-119, 1983.
42. O'Connor DT, Levine GL, Frigon RP: Homologous radioimmunoassay of human plasma dopamine beta-hydroxylase: analysis of homospecific activity, circulating plasma pool and intergroup differences based on race, blood pressure, and cardiac function. J Hypertension 1:227-233, 1983.
43. Snavely M, Mahan LC, O'Connor DT, Insel PA: Selective down regulation of adrenergic receptor subtypes in tissues from rats with pheochromocytoma. Endocrinol 113:354-361, 1983.
44. Bernstein KN, Barg AP, O'Connor DT: Nadolol: Evidence for sympathetic nerve inhibition by a beta blocker in essential hypertension. J Hypertension 1:291-296, 1983.
45. O'Connor DT: Chromogranin: widespread immunoreactivity in polypeptide hormone producing tissues and in serum. Regulatory Peptides 6:263-280, 1983.
46. O'Connor DT: Renal blood flow during nadolol administration. (Letter to the Editor) N Engl J Med 308:49, 1983.
47. O'Connor DT, Burton DG, Deftos LJ: Chromogranin A: Immunohistology reveals its universal occurrence in normal polypeptide hormone producing endocrine glands. Life Sci 33:1657-1663, 1983.
48. O'Connor DT, Burton DG, Deftos LJ: Immunoreactive chromogranin A in diverse polypeptide hormone producing human tumors and normal endocrine tissues. J Clin Endocrinol Metab 57:1084-1986, 1983.
1984 49. Sugino G, Barg AP, O'Connor DT: Renal perfusion is preserved during
cardioselective beta blockade with metoprolol in hypertension. Am J Kidney Dis III:357-361, 1984.
50. O'Connor DT, Frigon RP, Sokoloff RL: Human chromogranin A: purification and characterization from catecholamine storage vesicles of pheochromocytoma. Hypertension 6:2-12, 1984.
51. O'Connor DT, Frigon RP: Chromogranin A, the major catecholamine storage vesicle soluble protein: multiple size forms, subcellular storage and regional distribution in chromaffin and nervous tissue elucidated by radioimmunoassay. J Biol Chem 259:3237-3247, 1984.
52. Bernstein KN, O'Connor DT: Antiadrenergic antihypertensive drugs: their effects on renal function. Ann Rev Pharmacol Toxicol 24:105-120, 1984.
53. Serck-Hanssen G, O'Connor DT: Immunological identification and characterization of chromogranins coded by poly (A)-mRNA from bovine adrenal medulla and pituitary gland and human phaeochromocytoma. J Biol Chem 259:11597-11600, 1984.
54. O'Connor DT, Parmer RJ, Deftos LJ: Chromogranin A: studies in the endocrine system. Trans Assoc Am Physicians 97:242-250, 1984.
55. O'Connor DT: Chromogranin A: Implications for hypertension. J Hypertension 2(Suppl. 3):147-150, 1984.
O'Connor, Daniel T.
14
56. O'Connor DT, Mosley C, Cervenka J, Bernstein K: Contrasting renal hemodynamic responses to the angiotensin converting enzyme inhibitor enalapril and the beta adrenergic antagonist metoprolol in essential hypertension. J Hypertension 2(Suppl.):89-92, 1984.
57. O'Connor DT, Bernstein KN: Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. N Engl J Med 311:764-770, 1984. (topic of editorial in same issue)
58. Mosley C, O'Connor DT, Taylor A, Slutsky R, Cervenka J: Comparative effects of antihypertensive therapy with guanabenz and propranolol on renal vascular resistance and left ventricular mass. J Cardiovasc Pharmacol 6:s757-s761, 1984.
1985 59. Parmer R, Mosley C, O'Connor DT: Enkephalins in pheochromocytoma: studies
in a rat model. Clin Exp Hypertension A7:483-512, 1985. 60. Sokoloff RL, Frigon RP, O'Connor DT: Dopamine beta-hydroxylase: structural
comparisons of membrane bound versus soluble forms from adrenal medulla and pheochromocytoma. J Neurochem 44:441-450, 1985.
61. Kruggel W, O'Connor DT, Lewis R: The amino terminal sequences of bovine and human chromogranin A and secretory protein I are identical. Biochem Biophys Res Commun 127:380-383, 1985.
62. O'Connor DT: Plasma chromogranin A: Initial studies in human hypertension. Hypertension 7:I76-I79, 1985.
1986 63. O'Connor DT, Deftos LJ: Secretion of chromogranin A by peptide producing
endocrine neoplasms. N Engl J Med 314:1145-1151, 1986. 64. O'Connor DT, Levy B, Smith D, Winer N: Initial combination therapy for
hypertension: efficacy and metabolic advantages. Curr Ther Res 39:195-207, 1986.
65. Deftos LJ, Murray S, Burton DG, Parmer RJ, O'Connor DT: A cloned chromogranin A cDNA detects a 2.3 kb mRNA in diverse neuroendocrine tissues. Biochem Biophys Res Commun 137:418-423, 1986.
66. Sobol RE, O'Connor DT, Addison J, Suchocki K, Royston I, Deftos LJ: Elevated serum chromogranin A concentrations in small-cell lung carcinoma. Ann Int Med 105:698-700, 1986.
1987 67. Lauweryns JM, Van Ranst L, Lloyd R, O'Connor DT: Chromogranin in
bronchopulmonary neuroendocrine cells: Immunocytochemical detection in human, monkey and pig respiratory mucosa. J Histochem Cytochem 35:113-118, 1987.
68. Eiden L, Huttner W, Mallet J, O'Connor DT, Winkler H, Zanini A: A nomenclature proposal for the chromogranin/secretogranin proteins. Neurosci 21:1019-1021, 1987.
69. Murray S, Deaven LL, Burton DG, O'Connor DT, Mellon P, Deftos LJ: The gene for human chromogranin A is located on chromosome 14. Biochem Biophys Res Commun 142:141-146, 1987.
70. Deftos LJ, Bjornsson B, Burton DG, O'Connor DT, Copp DH: Chromogranin A is present in and released by fish endocrine tissue. Life Sci 40:2133-2136, 1987.
71. Schober M, Fischer-Colbrie R, Schmid KW, Bussolati G, O'Connor DT, Winkler H: Comparison of chromogranins A, B, and secretogranin II in human adrenal medulla and pheochromocytoma. Lab Invest 57:385-391, 1987.
72. O'Connor DT, Strause L, Saltman P, Parmer RJ, Cervenka J: Serum zinc is unaffected by effective captopril treatment of hypertension. J Clin Hypertension 3:405-408, 1987.
O'Connor, Daniel T.
15 15
73. Kemper CM, O'Connor DT, Westlund KN: Immunocytochemical localization of dopamine-beta-hydroxylase in neurons of the human brain stem. Neurosci 23:981-989, 1987.
1988 74. Parmer RJ, O'Connor DT: Enkephalins in human phaeochromocytoma:
localization in immunoreactive high molecular weight form to the soluble core of chromaffin granules. J Hypertension 6:187-198, 1988.
75. Sullivan PA, Dineen M, Cervenka J, O'Connor DT: Effects of fosinopril, a once-daily angiotensin-converting enzyme inhibitor, on resting and exercise-induced changes of blood pressure, hormonal variables, and plasma potassium in essential hypertension. Am J Hypertension 1:280S-283S, 1988.
76. Powers RE, Struble RG, Casanova MF, O'Connor DT, Kitt CA, Price DL: Innervation of human hippocampus by noradrenergic systems: normal anatomy and structural abnormalities in aging and in Alzheimer's disease. Neuroscience 25:401-417, 1988.
77. Deftos LJ, Linnoila RI, Carney DN, Burton DW, Leong SS, O'Connor DT, Murray WW, Gazdar AF: Demonstration of chromogranin A in human neuroendocrine cell lines by immunohistology and immunoassay. Cancer 62:92-97, 1988.
78. Weiler R, Fischer-Colbrie R, Schmid KW, Feichtinger H, Bussolati G, Grimelius L, Krisch K, Kerl H, O'Connor DT, Winkler H: Immunological studies on the occurrence and properties of chromogranin A and B and secretogranin II in endocrine tumors. Am J Surg Pathol 12:877-884, 1988.
79. O'Connor DT, Subramani S: Do transcriptional enhancers also augment DNA replication? Nucl Acids Res 16(23):11207-11222, 1988.
80. Simonsson M, Ericksson S, Hakanson R, Lind T, Lonroth H, Lundell L, O'Connor DT, Sundler F: Endocrine cells in the human oxyntic mucosa: a histochemical study. Scand J Gastroenterol 23:1089-1099, 1988.
1989 81. Takiyyuddin MA, Cervenka JH, Dinh TQ, Witztum J, O'Connor DT: Selective
alpha-blockade versus angiotensin-converting enzyme inhibition as initial antihypertensive therapy. Effects on circulating lipoproteins. Am J Med 86(S 1B):32-35, 1989.
82. Gifford RW, Kirkendall W, O'Connor DT, Weidman W: Office evaluation of hypertension. A statement for health professionals by a writing group of the Council for High Blood Pressure Research, Am Heart Assn. Hypertension 13:283-293, 1989. Circulation 79:721-731, 1989.
83. Powers RE, O'Connor DT, Price DL: Noradrenergic systems in human cerebellum. Brain Research 481:194-199, 1989.
84. Sullivan PA, Cervenka J, O'Connor DT, Dineen M: Fosenopril, an angiotensin converting enzyme inhibitor, and propranolol: comparative effects at rest and during exercise on blood pressure, hormonal variables and plasma potassium in essential hypertension. Cardiovasc Drugs & Therapy 3:57-62, 1989.
85. Parmer RJ, Koop AH, Handa MT, O'Connor DT: Molecular cloning of chromogranin A from rat pheochromocytoma cells. Hypertension 14:435-44, 1989.
86. Nanes MS, O'Connor DT, Marx SJ: Plasma chromogranin A in primary hyperparathyroidism. J Clin Endo Metab 69:950-5, 1989.
87. Deftos LJ, O'Connor DT, Wilson CB, Fitzgerald PA: Human pituitary tumors secrete chromogranin A. J Clin Endo Metab 68:869-72, 1989.
88. Dimsdale JE, O'Connor DT, Ziegler M, Mills P: Does chromogranin A respond to short-term mild physiologic challenge? Neuropsychopharmacology. 2:237-40, 1989.
89. O'Connor DT, Pandian MR, Carlton E, Cervenka JH, Hsiao RJ: Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. Clin Chem 35:1631-7, 1989.
O'Connor, Daniel T.
16
90. Jengeleski CA, Powers RE, O'Connor DT, Price DL: Noradrenergic innervation of human pineal gland: abnormalities in aging and Alzheimer's disease. Brain Research 481:378-82, 1989.
1990 91. Polikar R, Kennedy B, Ziegler M, O'Connor DT, Smith J, Nicod P. Plasma
norepinephrine kinetics, dopamine-beta-hydroxylase, and chromogranin A in hypothyroid patients before and following replacement therapy. J Clin Endo Metab 70: 277-281, 1990.
92. Takiyyuddin MA, Cervenka JH, Hsiao RJ, Barbosa JA, Parmer RJ, O'Connor DT. Chromogranin A: storage and release in hypertension. Hypertension 15: 237-246, 1990.
93. Takiyyuddin MA, Cervenka JH, Sullivan PA, Pandian MR, Barbosa JA, O'Connor DT: Is physiologic sympathoadrenal catecholamine release exocytotic in humans? Circulation 81:185-195, 1990.
94. Carmichael SW, Stoddard SL, O'Connor DT, Yaksh TL, Tyce GM: The secretion of catecholamines, chromogranin A and neuropeptide Y from the adrenal medulla of the cat via the adrenolumbar vein and thoracic duct: different anatomic routes based on size. Neuroscience 34:433-440, 1990.
95. Hsiao RJ, Mezger MS, O'Connor DT: Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney International 37:955-964, 1990.
96. Parmer RJ, Cervenka JH, Stone RA, O'Connor DT: Autonomic function in hypertension: are there racial differences? Circulation 81:1305-1311, 1990.
97. Ziegler MG, Kennedy B, Morrissey E, O'Connor DT: Norepinephrine clearance, chromogranin A and dopamine-beta-hydroxylase in renal failure. Kidney International 37:1357-1362, 1990.
98. Hsiao RJ, Seeger RC, Yu AL, O'Connor DT: Chromogranin A in children with neuroblastoma: serum concentration parallels disease stage and predicts survival.
J Clin Invest 85:1555-1559, 1990. 99. Stabile BE, Howard TJ, Passaro E, O'Connor DT: Source of plasma
chromogranin A elevation in gastrinoma patients. Arch Surg 125:451-3, 1990. 100. Wu HJ, Parmer RJ, Koop AH, Rozansky DJ, O'Connor DT: Molecular cloning,
structure and expression of dopamine beta-hydroxylase from bovine adrenal medulla. J Neurochem 55:97-105, 1990.
101. Takiyyuddin MA, Cervenka JH, Pandian MR, Stuenkel CA, Neumann HPH, O'Connor DT: Neuroendocrine sources of chromogranin A in normal man: clues from selective stimulation of endocrine glands. J Clin Endo Metab 71:360-9, 1990.
102. Hsiao RJ, Neumann HPH, Parmer RJ, Barbosa JA, O'Connor DT: Chromogranin A in familial pheochromocytoma: diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution. Amer J Med 88:607-613, 1990.
103. Mullen JT, O'Connor DT: Potassium effects on blood pressure: is the conjugate anion important? J Human Hypertension 4:589-96, 1990.
104. Lahr G, Heiss C, Mayerhofer A, Schilling K, Parmer RJ, O'Connor DT, Gratzl M: Chromogranin A in the olfactory system of the rat. Neuroscience 39:605-611, 1990.
105. Powers RE, O'Connor DT, Price DL: Noradrenergic innervation of human inferior olivary complex. Brain Research 523:151-5, 1990.
1991 106. Hsiao RJ, Parmer RJ, Takiyyuddin MA, O'Connor DT: Chromogranin A storage
and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine 70:33-45, 1991.
107. Barbosa JA, Gill BM, Takiyyuddin MA, O'Connor DT: Chromogranin A: posttranslational modifications in secretory granules. Endocrinology 128:174-190, 1991.
O'Connor, Daniel T.
17 17
108. Takiyyuddin MA, Neumann HPH, Cervenka JH, Kennedy B, Dinh TQ, Ziegler MG, Baron AD, O'Connor DT: Ultradian variations of chromogranin A in humans. Am J Physiol 30:r939-r944, 1991.
109. Takiyyuddin MA, Baron AD, Cervenka JH, Barbosa JA, Neumann HPH, Parmer RJ, Sullivan PA, O'Connor DT: Suppression of chromogranin A release from neuroendocrine sources in man: pharmacological studies. J Clin Endo Metab 72:616-622, 1991.
110. Gill BM, Barbosa JA, Dinh TQ, Garrod S, O'Connor DT: Chromogranin B: isolation from pheochromocytoma, N-terminal sequence, tissue distribution and secretory vesicle processing. Regul Peptides 33:223-35, 1991.
111. Shults CW, O'Connor DT, Baird A, Hill R, Goetz CG, Watts RL, Klawans HL, Carvey PM, Bakay RM, Gage FH, U HS: Clinical improvement in Parkinsonian patients undergoing adrenal to caudate transplantation is not reflected by chromogranin A or basic fibroblast growth factor in ventricular fluid. Exp Neurol 111:276-81, 1991.
112. Ito MK, O'Connor DT: Skin pretreatment and the use of transdermal clonidine. Amer J Med 91(1A):1A-42S-1A-49S, 1991.
113. Wand GS, Takiyyuddin M, O'Connor DT, Levine MA: A proposed role for chromogranin A as a glucocorticoid-responsive inhibitor of proopiomelanocortin secretion. Endocrinology 128:1345-51, 1991.
114. McGrath-Linden SJ, Johnston CF, O'Connor DT, Shaw C, Buchanon KD: Pancreastatin immunoreactivity in human carcinoid disease. Regul Peptides 33:55-70, 1991.
115. Wu HJ, Rozansky DJ, Parmer RJ, Gill BM, O'Connor DT: Structure and function of the chromogranin A gene: clues to evolution and tissue-specific expression. J Biol Chem 266:13130-4, 1991.
116. Rogers PJ, Tyce GM, Weinshilboum RM, O'Connor DT, KR Bailey, Bove AA: Catecholamine metabolic pathways and exercise training: plasma and urinary catecholamines, metabolic enzymes, and chromogranin A. Circulation 84:2346-56, 1991.
117. O'Connor DT, Klein RL, Thureson-Klein AK, Barbosa JA: Chromogranin A: localization and stoichiometry in large dense core catecholamine storage vesicles from sympathetic nerve. Brain Research 567:188-196, 1991.
1992 118. Videen JS, Mezger MS, Chang YM, O'Connor DT: Calcium and catecholamine
interactions with adrenal chromogranins: comparison of driving forces in binding and aggregation. J Biol Chem 267:3066-73, 1992.
119. Van Kammen DP, Peters J, Yao J, Neylan T, Beuger M, Pontius E, O'Connor DT: CSF chromogranin A-like immunoreactivity in schizophrenia: assessment of clinical and biochemical relationships. Schizophrenia Research 6:31-9, 1992.
120. Gill BM, Barbosa JA, Hogue-Angeletti R, Varki N, O'Connor DT: Chromogranin A epitopes: clues from synthetic peptides and peptide mapping. Neuropeptides 21:105-18, 1992.
121. Blind E, Schmidt-Gayk H, Sinn H-P, O'Connor DT, Raue F: Chromogranin A as a tumor marker in medullary thyroid carcinoma. Thyroid 2:5-10, 1992.
122. Van Kammen DP, O'Connor DT, Neylan TC, Mouton A, Gurklis JA, Gilbertson MW, Peters JL. CSF chromogranin A-like immunoreactivity in schizophrenia: relationships with REM latency and slow wave sleep. Psychiatry Research 42:53-63, 1992.
123. Dimsdale JE, O'Connor DT, Ziegler M, Mills P: Chromogranin A correlates with norepinephrine release rate. Life Sci 51:519-25, 1992.
124. Syversen U, Waldum HL, O'Connor DT: Rapid, high-yield isolation of human chromogranin A from chromaffin granules of pheochromocytomas. Neuropeptides 22:235-240, 1992.
125. Bender H, Maier A, Wiedenmann B, O'Connor DT, Messner K, Schmidt-Gayk H: Immunoluminometric assay of chromogranin A in serum with commercially available reagents. Clin. Chem. 38: 2267-2272, 1992.
O'Connor, Daniel T.
18
126. Sullivan PA, Grosch C, Lawless D, O'Connor DT: Short-term strenuous exercise training: effects on blood pressure and hormonal levels in mild hypertension. Ir J Med Sci 161:666-9, 1992.
1993 127. Parmer RJ, Miles LA, Xi XP, Gill BM, Wu HJ, O'Connor DT: Processing of
chromaffin granule proteins: A profusion of proteases? Neurochem. Int. 22:361-367, 1993.
128. O'Connor DT, Kailasam MT, Thal LJ: Cerebrospinal fluid chromogranin A is unchanged in Alzheimer dementia. Neurobiology of Aging 14:267-269, 1993.
129. Takiyyuddin MA, DeNicola L, Gabbai FB, Dinh TQ, Kennedy B, Ziegler MG, Sabban EL, Parmer RJ, O'Connor DT: Catecholamine secretory vesicles. Augmented chromogranins and amines in secondary hypertension. Hypertension 21:674-9, 1993.
130. MA Testa, RB Anderson, JF Nackley, NK Hollenberg, and the Quality-of-Life Hypertension Study Group. Quality of life and antihypertensive therapy in men: a comparison of captopril with enalapril. New Engl J Med 328:907-13, 1993.
131. Simon-Chazottes D, Wu H-J, Parmer RJ, Rozansky DJ, Szpirer J, Kurtz TW, Szpirer C, Guenet J-L, O'Connor DT: Assignment of the chromogranin A locus to homologous regions on mouse chromosome 12 and rat chromosome 6. Genomics 17:252-255, 1993.
132. O'Connor DT, Cervenka JH, Stone RA, Parmer RJ, Franco-Bourland R, Madrazo I, Langlais PJ: Chromogranin A immunoreactivity in human cerebrospinal fluid: Properties, relationship to noradrenergic neuronal activity, and variation in neurologic disease. Neuroscience 56:999-1007, 1993.
133. Syversen U, Jacobsen MB, Hanssen LE, O'Connor DT, Waldum HL: Chromogranin A and pancreastatin-like immunoreactivity in human carcinoid disease. European Journal of Gastroenterology & Hepatol 5:1043-1050, 1993.
1994 134. O'Connor DT, Cervenka JH, Stone RA, Levine GL, Parmer RJ, Franco-Bourland
R, Madrazo I, Langlais P, Robertson D, Biaggioni I: Dopamine beta-hydroxylase immunoreactivity in human cerebrospinal fluid: properties, relationship to central noradrenergic neuronal activity, and variation in Parkinson's disease and congenital dopamine ß-hydroxylase deficiency. Clinical Science 86:149-158, 1994.
135. Garcia GE, Gabbai FB, O'Connor DT, Dinh TQ, Kennedy B, Ziegler MG, Takiyyuddin MA: Does chromostatin Influence catecholamine release or blood pressure in vivo? Peptides 15:195-197, 1994.
136. Takiyyuddin MA, Brown MR, Dinh TQ, Cervenka JH, Braun SD, Parmer RJ, Kennedy B, O'Connor DT: Sympatho-adrenal secretion in humans: factors governing catecholamine and storage vesicle peptide co-release. J Autonom Pharmacol 14:177-90, 1994.
137. Van Kammen DP, Agren H, Yao JK, O'Connor DT, Gurklis JA, Peters JL: Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia. Am J Psychiatry 151:379-84, 1994.
138. Van Kammen DP, Kelley ME, Gilbertson MW, Gurklis J, O'Connor DT. CSF dopamine beta-hydroxylase in schizophrenia: associations with premorbid functioning and brain computerized tomography scan measures. American J Psychiatry 15:372-8, 1994.
139. Wu HJ, Rozansky DJ, Webster NJG, O'Connor DT. Cell type-specific gene expression in the neuroendocrine system: A neuroendocrine-specific regulatory element in the promoter of chromogranin A, a ubiquitous secretory granule core protein. J Clin Invest 94:118-129, 1994.
140. Kailasam MT, Lin MC, Cervenka JH, Parmer RJ, Kennedy BP, Ziegler MG, O'Connor DT. Effects of an oral prostaglandin E agonist on blood pressure and
O'Connor, Daniel T.
19 19
its determinants in essential hypertension. J of Hum Hypertension 8:515-520, 1994.
141. Rozansky DJ, Wu HJ, Tang K, Parmer RJ, O'Connor DT. Glucocorticoid activation of chromogranin A gene expression: identification and characterization of a novel glucocorticoid response element. J Clin Invest 94:2357-2368, 1994.
142. Wu RA, Kailasam MT, Cervenka JH, Parmer RJ, Kennedy BP, Ziegler MG, O'Connor DT. Does lipophilicity of angiotensin converting enzyme inhibitors selectively influence autonomic neural function in human hypertension? J Hypertension 12:1243-1247, 1994.
143. Syversen, U; Jacobsen, MB; O’Connor, DT; Ronning, K; Waldum, HL. Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroenndocrine neoplasia. Neuropeptides. 26:201-206, 1994.
1995 144. Cubeddu LX, O'Connor DT, Parmer RJ. Plasma chromogranin A: a marker of
serotonin release and of emesis associated with cisplatin chemotherapy. J Clin Oncology 13:681-7, 1995.
145. Kailasam MT, Parmer RJ, Stone RA, Shankel S, Kennedy BP, Ziegler MG, O'Connor, DT: Factitious pheochromocytoma: novel mimickry by valsalva manuever and clues to diagnosis. American Journal of Hypertension 8:651-655, 1995.
146. Kailasam MT, Parmer RJ, Cervenka JH, Wu RA, Ziegler MG, Kennedy BP, Adegbile IA, O'Connor DT. Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic function in human hypertension. Hypertension 26:143-149, 1995.
147. Takiyyuddin MA, Parmer RJ, Kailasam MT, Cervenka JH, Kennedy B, Ziegler MG, Lin, M-C, Li J, Grim CE, Wright FA, O'Connor DT. Chromogranin A in human hypertension: influence of heredity. Hypertension 26:213-220, 1995.
148. Wu HJ, Mahata SK, Mahata M, Webster NJG, Parmer RJ, O'Connor DT. A functional cyclic AMP response element plays a crucial role in neuroendocrine cell type-specific expression of the secretory granule protein chromogranin A. J Clin Invest 96:568-78, 1995.
149. Cubeddu LX, O'Connor DT, Hoffmann L, Parmer RJ. Plasma chromogranin A marks emesis and serotonin release associated with dacarbazine and nitrogen mustard but not with cyclophosphamide-based chemotherapies. British J Cancer 72:1033-8, 1995.
1996 150. Mahata SK, Kozak CA, Szpirer J, Szpirer C, Modi WS, Gerdes H-H, Huttner WB,
O'Connor DT. Dispersion of chromogranin/secretogranin secretory protein family loci in mammalian genomes. Genomics 33:135-139, 1996.
151. Brinton TJ, Kailasam MT, Wu RA, Cervenka JH, Chio S-S, Parmer RJ, De Maria AN, O'Connor DT. Arterial compliance by cuff sphygmomanometer: application to hypertension, and early changes in subjects at genetic risk. Hypertension 28:599-603, 1996.
152. Eskeland NL, Zhou A, Dinh TQ, Parmer RJ, Mains RE, O'Connor DT. Chromogranin A processing and secretion: specific role of endogenous and exogenous prohormone convertases in the regulated secretory pathway. J Clin Invest 98:148-156, 1996.
153. Mahata MM, Mahata SK, Parmer RJ, O'Connor DT. Vesicular monoamine transport inhibitors: novel action to inhibit catecholamine release by calcium channel blockade. Hypertension 28:414-420, 1996.
154. Tang K, Wu H, Mahata SK, Taupenot L, Parmer RJ, O'Connor DT. Stimulus-transcription coupling in pheochromocytoma cells. Promoter region-specific activation of chromogranin A biosynthesis. J Biol Chem 271:28382-90, 1996.
O'Connor, Daniel T.
20
1997 155. Parmer RJ, Mahata M, Mahata SK, Sebald MT, O'Connor DT, Miles LA. Tissue
plasminogen activator (t-PA) is targeted to the regulated secretory pathway. Catecholamine storage vesicles as a reservoir for the rapid release of t-PA.
J Biol Chem 272:1976-1982, 1997. 156. Brinton TJ, Cotter B, Kailasam MT, Brown DL, Chio SS, O’Connor DT, and
DeMaria AN. Development and Validation of a Noninvasive Method to Determine Arterial Pressure and Vascular Compliance. Am J Cardiol 80:323-330, 1997.
157. Tang K, Wu HJ, Mahata SK, Mahata M, Gill BM, Parmer RJ, and O’Connor DT. Stimulus Coupling to Transcription Versus Secretion in Pheochromocytoma Cells. Convergent and Divergent Signal Transduction Pathways and the Crucial Roles for Route of Cytosolic Calcium Entry and Protein Kinase C. J Clin Invest 100:1180-92, 1997.
158. Mahata SK, O’Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, Gill BM, Parmer RJ. Novel autocrine feedback control of catecholamine release: a discrete chromogranin A fragment is a non-competitive nicotinic cholinergic antagonist. J Clin Invest 100:1623-33, 1997 (corresponding author).
1998 159. Toto R, Shultz P, Raij L, Mitchell H, Shaw W, Ramjit D, Toh J, Shahinfar S, for
the Collaborative Group*. Efficacy and Tolerability of Losartan in Hypertensive Patients with Renal Impairment. Hypertension. 31:684-691, 1998.
160. Taupenot L, Mahata SK, Wu H, and O’Connor DT. Peptidergic Activation of Transcription and Secretion in Chromaffin Cells: Cis- and Trans- Signaling Determinants of Pituitary Adenylyl Cyclase Activating Polypeptide (PACAP). J Clin Invest 101:863-876, 1998.
161. Lacy F, O’Connor DT, and Schmid-Schonbein G. Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. J Hypertension 16:291-303, 1998.
162. Tang K, Wu H, Mahata SK, O'Connor DT. A Crucial Role for the Mitogen-Activated Protein Kinase Pathway in Nicotinic Cholinergic Signaling to Secretory Protein Transcription in Pheochromocytoma Cells. Molec Pharmacol 54:59-69, 1998.
163. Dao TT, Kailasam MT, Parmer RJ, Le HV, LeVerge R, Kennedy BP, Ziegler MG, Insel PA, Wright FA, O'Connor DT. Expression of altered alpha-2-adrenergic phenotypic traits in normotensive humans at genetic risk of hereditary (essential) hypertension. J Hypertension 16:779-792, 1998.
164. Cubells JF, Van Kammen DP, Kelley ME, Anderson GM, O'Connor DT, Price LH, Malison R, Rao PA, Kobayashi K, Toshiharu N, Gelernter J. Dopamine beta-hydroxylase: two polymorphisms in linkage disequilibrium at the structural gene DBH associate with biochemical phenotypic variation. Hum Genet 102:533-540, 1998.
165. Kong C, Gill BM, Rahimpour R, Xu L, Feldman RD, Xiao Q, McDonald TJ, Taupenot L, Mahata SK, Singh B, O'Connor DT, Kelvin DJ. Secretoneurin and chemoattractant receptor interactions. J Neuroimmunology 88:91-98, 1998.
166. Kailasam, MT, Martinez JA, Cervenka JH, Yen SSC, O'Connor DT, Parmer RJ. Racial differences in renal kallikrein excretion: Effect of the ovulatory cycle. Kidney International 54:1652-1658, 1998.
167. Tsigelny I, Mahata SK, Taupenot L, Preece NE, Mahata M, Khan I, Parmer RJ, O'Connor DT. Mechanism of Action of Chromogranin A on Catecholamine
O'Connor, Daniel T.
21 21
Release: Molecular Modeling of the Catestatin Region Reveals a Beta-strand/Loop/Beta-strand Structure Secured by Hydrophobic Interactions and Predictive of Activity. Regulatory Peptides 77:43-53, 1998.
168. M Höcker, R Raychowdhury, T Plath, H Wu, DT O'Connor, B Wiedenmann, S Rosewicz, and TC Wang. Sp1 and CREB Mediate Gastrin-dependent Regulation of Chromogranin A Promoter Activity in Gastric Carcinoma Cells. J. Biol. Chem 273: 34000-34007, 1998.
169. Mahata, M, Mahata, SK, Parmer, RJ, O'Connor, DT. Proadrenomedullin N-terminal 20 peptide: minimal active region to regulate nicotinic receptors. Hypertension 32:907-16, 1998.
170. Kennedy, BP, Mahata, SK, O'Connor, DT, Ziegler, MG. Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo. Peptides 19:1241-8, 1998.
1999 171. Mahata SK, Mahata M, Wu H, Parmer RJ, O'Connor DT. Neurotrophin
activation of Catecholamine storage vesicle protein gene expression: Signaling to chromogranin A biosynthesis. Neuroscience 88:405-424, 1999.
172. Mahata, SK; Mahata, M; Livsey, CV; Gerdes, HH; Huttner, WB; O’Connor, DT. Neuroendocrine cell type-specific and inducible expression of the secretogranin II gene: Crucial role of cyclic adenosine monophosphate and serum response elements. Endocrinology 140:739-749, 1999.
173. Subbiah Pugazhenthi, Tracy Boras, Daniel O'Connor, Mary Kay Meintzer, Kim A. Heidenreich, and Jane E.-B. Reusch. Insulin-like Growth Factor I-mediated Activation of the Transcription Factor cAMP Response Element-binding Protein in PC12 Cells. Involvement Of P38 Mitogen-Activated Protein Kinase-Mediated Pathway J. Biol. Chem. 274:2829-2837, 1999.
174. Sushil K. Mahata, Manjula Mahata, Robert J. Parmer, and Daniel T. O'Connor. Desensitization Of Catecholamine Release. The Novel Catecholamine Release-Inhibitory Peptide Catestatin (Chromogranin A344-364) Acts At The Receptor To Prevent Nicotinic Cholinergic Tolerance. J. Biol. Chem. 274:2920-2928, 1999.
175. Fred A. Wright, Daniel T. O’Connor, Elizabeth Roberts, Greg Kutey, Charles C. Berry, Lisa U. Yoneda, David Timberlake, Gunther Schlager. Genome Scan for Blood Pressure Loci in Mice. Hypertension 34:625-630, 1999.
176. Laurent Taupenot, Manjula Mahata, Sushil Mahata, Daniel T. O’Connor. Time-Dependent Effects of the Neuropeptide PACAP on Catecholamine Secretion. Stimulation and Desensitization. Hypertension 34:1-11, 1999.
177. Rainer Büscher, Volker Herrmann, Kevin M. Ring, Mala T. Kailasam, Daniel T. O’Connor, Robert J. Parmer, and Paul Insel. Variability in Phenylephrine Response and Essential Hypertension: A Search for Human α1B–Adrenergic Receptor Polymorphisms. J Pharmacol Exper Therap 291:793-798, 1999.
178. Daniel T. O’Connor, Marwan A. Takiyyuddin, Morton P. Printz, Thai Q. Dinh, Juan A. Barbosa, David J. Rozansky, Sushil K. Mahata, Hongjiang Wu, Brian P. Kennedy, Michael G. Ziegler, Fred A. Wright, Gunther Schlager, Robert J. Parmer. Catecholamine storage vesicle protein expression in genetic hypertension. Blood Pressure 8:285-95, 1999.
179. WJ Elliott, for the Eprosartan Study Group. Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. Journal of Human Hypertension 13:413-417, 1999.
2000
O'Connor, Daniel T.
22
180. CK Song, JA Martinez, MT Kailasam, TT Dao, CM Wong, RJ Parmer, and DT O’Connor. Renal kallikrein excretion: role of ethnicity, gender, environment, and genetic risk of hypertension. J Human Hypertension 14:461-8, 2000.
181. CV Taylor, L Taupenot, SK Mahata, M Mahata, H Wu, Q Jiang, C Caporale, RJ Parmer, VY Hook, DT O’Connor. Formation of the catecholamine release-inhibitory peptide catestatin from chromogranin A: determination of cleavage sites in hormone storage granules. J Biol Chem 275:22905-15, 2000.
182. SK Mahata, M Mahata, DT O'Connor. Primary structure and function of the catecholamine release-inhibitory peptide catestatin (chromogranin A344-364): identification of amino acid residues crucial for activity. Molec Endocrinology 14:1525-35, 2000. (cover article)
183. V Herrmann, R Buscher, MM Go, KM Ring, JK Hofer, MT Kailasam, DT O'Connor, RJ Parmer, and PA Insel. Beta2-adrenergic receptor polymorphisms at codon 16, cardiovascular phenotypes and essential hypertension in Caucasians and African Americans. American Journal of Hypertension 13:1021-1026, 2000.
184. NR Mahapatra, M Mahata, AK Datta, H-H Gerdes, WB Huttner, DT O'Connor, SK Mahata. Neuroendocrine cell type-specific and inducible expression of the chromogranin B gene: crucial role of the proximal promoter. Endocrinology 141:3668-78, 2000.
185. RJ Parmer, M Mahata, Y Gong, SK Mahata, Q Jiang, DT O'Connor, XP Xi, and LA Miles. Processing of chromogranin A by plasmin provides a novel mechanism for regulating catecholamine secretion. Journal of Clinical Investigation 106:907-915, 2000.
186. L Taupenot, SK Mahata, M Mahata, RJ Parmer, DT O'Connor. Interaction of the catecholamine release-inhibitory peptide catestatin (human chromogranin A352-272) with the chromaffin cell surface and Torpedo electroplax: implications for nicotinic cholinergic antagonism. Regulatory Peptides. 95:9-17, 2000.
187. MT Kailasam, RJ Parmer, EA Tyrell, RR Henry, and DT O'Connor. Circulating Amylin In Human Essential Hypertension: Heritability and Early Increase In Individuals At Genetic Risk. J Hypertension 18:1611-20, 2000.
188. F Lacy, MT Kailasam, DT O'Connor, GW Schmid-Schönbein, RJ Parmer. Plasma Hydrogen Peroxide Production in Human Essential Hypertension. Role of Heredity, Gender, and Ethnicity. Hypertension 36:878-884, 2000.
189. F Rao, HR Keiser, DT O'Connor. Malignant Pheochromocytoma: Chromaffin Granule Transmitters and Response to Treatment. Hypertension 36:1045-1052, 2000.
2001 190. DT O’Connor, EA Tyrell, MT Kailasam, LM Miller, JA Martinez, RR Henry, RJ
Parmer, FB Gabbai. Early alteration in glomerular reserve in humans at genetic risk of essential hypertension: mechanisms and consequences. Hypertension. 37:898-906, 2001.
191. Agodoa, Lawrence, O’Connor, Daniel, et. al. (African American Study of Kidney Disease and Hypertension [AASK] Study Group; alphabetical authorship). Effect of Ramipril versus Amlodipine on Renal Outcomes in Hypertensive Nephrosclerosis: a Randomized, Controlled Trial. J Amer Med Assn 285:2719-2724, 2001.
192. Q Jiang, L Taupenot, SK Mahata, M Mahata, DT O’Connor, LA Miles, RJ Parmer. Proteolytic cleavage of chromogranin A by plasmin. Selective liberation
O'Connor, Daniel T.
23 23
of a specific bioactive fragment that regulates catecholamine release. J Biol Chem 276:25022-9, 2001.
193. M Hocker, T Cramer, DT O’Connor, S Rosewicz, B Wiedenmann, TC Wang. Neuroendocrine-specific and gastrin-dependent expression of a chromogranin A-luciferase fusion gene in transgenic mice. Gastroenterology 121:43-55, 2001.
194. J Lewis, L Agodoa, D Cheek, T Greene, J Middleton, D O’Connor, A Ojo, R Phillips, M Sika, J Wright, and the AASK Study Group. Comparison of cross-sectional renal function measurements in blacks with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate. American Journal of Kidney Diseases 38:744-53, 2001.
2002 195. Carlos J. Herrero, Eva Ales, Antonio J. Pintado, Manuela G. Lopez, Esther
Garcia-Palomero, Sushil K. Mahata, Daniel T. O’Connor, Antonio G. Garcia, and Carmen Montiel. Modulatory Mechanism of the Endogenous Peptide Catestatin on Neuronal Nicotinic Acetylcholine Receptors and Exocytosis. Journal of Neuroscience 22:377-388, 2002.
196. Manjula Mahata, Nitish R. Mahapatra, Daniel T. O'Connor, and Sushil K. Mahata. Chromaffin Cell Catecholamine Secretion: Bisindolylmaleimide Compounds Exhibit Novel and Potent Antagonist Effects at the Nicotinic Cholinergic Receptor in Pheochromocytoma Cells. Molecular Pharmacology 61:1340-1347, 2002.
197. Daniel T. O’Connor, Mala T. Kailasam, Brian P. Kennedy, Michael G. Ziegler, Noboru Yanaihara, and Robert J. Parmer. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertension 20:1-11, 2002.
198. Laurent Taupenot, Kimberly L. Harper, Nitish R. Mahapatra, Robert J. Parmer, Sushil K. Mahata, and Daniel T. O’Connor. Identification of a novel sorting determinant for the regulated pathway in the secretory protein chromogranin A. J Cell Science 115:4827-4841, 2002.
199. JW Kusek, P Greene, SR Wang, G Beck, D West, K Jamerson, LY Agodoa, M Faulkner, B Level, for the African American Study of Kidney Disease and Hypertension Study Group. Cross-Sectional Study of Health-Related Quality of Life in African Americans with Chronic Renal Insufficiency: The African American Study of Kidney Diisease and Hypertension Trial. Amer Journal of Kidney Diseases 39:513-524, 2002.
200. JT Wright, L Agodoa, G Contreras, T Greene, JG Douglas, J Lash, O Randall, N Rogers, MC Smith, S Massry, for the African American Study of Kidney Disease and Hypertension Study Group. Successful Blood Pressure Control in the African American Study of Kidney Disease and Hypertension. Arch Internal Med 162:1636-1643, 2002.
201. JT Wright, G Bakris, T Greene, LY Agodoa, LJ Appel, J Charleston, D Cheek, JG Douglas-Baltimore, J Gassman, R Glassock, L Hebert, K Jamerson, J Lewis, RA Phillips, RD Toto, JP Middleton, SG Rostand, G Contreras, T Greene, JG Douglas, J Lash, O Randall, N Rogers, MC Smith, S Massry, for the African American Study of Kidney Disease and Hypertension Study Group. Effect of Blood Pressure Lowering and Antihypertensive drug Class on Progression of Hypertensive Kidney Disease – Results from the AASK Trial. JAMA 288:2421-2431, 2002.
2003
O'Connor, Daniel T.
24
202. Noha H. Farag, Manjula Mahata, Michael G. Ziegler, Daniel T. O'Connor, Paul J. Mills. Hormone replacement therapy increases renal kallikrein excretion in healthy postmenopausal women. Life Sciences 72:1279-1288, 2003.
203. Laurent Taupenot, Kimberly L. Harper, and Daniel T. O'Connor. The chromogranin-secretogranin family. New Engl J Med 348:1134-49, 2003.
204. Caroline M. Wong, Daniel T. O'Connor, Joseph A. Martinez, Mala T. Kailasam, and Robert J. Parmer. Diminished Renal Kallikrein Responses to Mineralocorticoid Stimulation in African-Americans: Determinants of an Intermediate Phenotype for Hypertension. Amer J Hypertension 16:281-289, 2003 (corresponding author).
205. Surin W. Chitbangonsyn, Payam Mahboubi, Darius Walker, Karin L. Diggle, David S. Timberlake, Robert J. Parmer, and Daniel T. O’Connor. Physical mapping of autonomic/sympathetic candidate genetic loci for hypertension in the human genome: A somatic cell radiation hybrid library approach. J Human Hypertension 17:319-324, 2003.
206. Nitish R. Mahapatra, Manjula Mahata, Daniel T. O’Connor, and Sushil K. Mahata. Secretin activation of chromogranin A gene transcription: identification of signaling pathways in cis and in trans. J Biol Chem 278:19986-94, 2003.
207. J Lee, CV Taylor, SP Gaucher, T Toneff, L Taupenot, S Yasothornsrikul, SK Mahata, C Sei, RJ Parmer, JM Neveu, WS Lane, BW Gibson, DT O’Connor, VY Hook. Primary Sequence Characterization of Catestatin Intermediates and Peptides Defines Proteolytic Cleavage Sites Utilized for Converting Chromogranin A into Active Catestatin Secreted from Neuroendocrine Chromaffin Cells. Biochemistry 42:6938-46, 2003.
208. Clifford Wong, Nitish Mahapatra, Surin Chitbangonsyn, Payam Mahboubi, Manjula Mahata, Sushil K. Mahata, and Daniel T. O’Connor. The angiotensin II receptor (Agtr1a): Functional regulatory polymorphisms in a locus genetically linked to blood pressure variation in the mouse. Physiological Genomics 14:83-93, 2003.
209. Sushil K Mahata, Nitish R Mahapatra, Manjula Mahata, Timothy C. Wang, Brian P. Kennedy, Michael G. Ziegler, and Daniel T. O’Connor. Catecholamine secretory vesicle stimulus-transcription coupling in vivo: demonstration by a novel transgenic promoter/photoprotein reporter, and inhibition of secretion and transcription by the chromogranin A fragment catestatin. J Biol Chem 278:32058-67, 2003.
210. Gina M. Schneider, David W. Jacobs, Richard N. Gevirtz, and Daniel T.
O'Connor. Cardiovascular hemodynamic response to repeated mental stress in normotensive subjects at genetic risk of hypertension: evidence of enhanced reactivity, blunted adaptation, and delayed recovery. J Human Hypertension 17:829-840, 2003.
211. Lea JP, Brown DT, Lipkowitz M, Middleton J, Norris K; for the African American Study of Kidney Disease and Hypertension Study Group. Preventing Renal Dysfunction in Patients with Hypertension: Clinical Implications from the Early AASK Trial Results. Am J Cardiovasc Drugs. 2003;3(3):193-200.
212. Appel LJ, Middleton J, Miller ER 3rd, Lipkowitz M, Norris K, Agodoa LY, Bakris G, Douglas JG, Charleston J, Gassman J, Greene T, Jamerson K, Kusek JW, Lewis JA, Phillips RA, Rostand SG, Wright JT. for the African American Study of Kidney Disease and Hypertension Study Group. The rationale and design of the AASK cohort study. J Am Soc Nephrol. 2003 Jul;14(7 Suppl 2):S166-72.
O'Connor, Daniel T.
25 25
213. Gassman JJ, Greene T, Wright JT Jr, Agodoa L, Bakris G, Beck GJ, Douglas J, Jamerson K, Lewis J, Kutner M, Randall OS, Wang SR. Design and statistical aspects of the African American Study of Kidney Disease and Hypertension for the African American Study of Kidney Disease and Hypertension Study Group. J Am Soc Nephrol. 2003 Jul;14(7 Suppl 2):S154-65.
2004 214. Lewis J, Greene T, Appel L, Contreras G, Douglas J, Lash J, Toto R, Van
Lente F, Wang X, Wright JT Jr; for the African American Study of Kidney Disease and Hypertension Study Group. A comparison of iothalamate-GFR and serum creatinine-based outcomes: acceleration in the rate of GFR decline in the African American Study of Kidney Disease and Hypertension. J Am Soc Nephrol. 2004 Dec;15(12):3175-83.
215. Gen Wen, Sushil K. Mahata, Peter E. Cadman, Manjula Mahata, Sajalendu Ghosh, Nitish R. Mahapatra, Fangwen Rao, Mats Stridsberg, Douglas W. Smith, Payam Mahboubi, Daniel T. O’Connor, and Bruce A. Hamilton. Both rare and common polymorphisms contribute functional variation at CHGA, a regulator of catecholamine physiology. Amer J Hum Genetics 74:197-207, 2004. (lead article)
216. Nicholas E. Preece, Minh Nguyen, Manjula Mahata, Sushil K. Mahata, Igor Tsigelny, and Daniel T. O’Connor. Conformational preferences of peptides derived from the catecholamine release-inhibitory (catestatin) region of chromogranin A. Regulatory Peptides 118:75-87, 2004.
217. Ryan S. Fries, Payam Mahboubi, Nitish R. Mahapatra, Sushil K. Mahata, Nicholas J. Schork, Geert W. Schmid-Schoenbein, and Daniel T. O’Connor. Neuroendocrine transcriptome in genetic hypertension: multiple changes in diverse adrenal physiological systems. Hypertension 43:1301-1311, 2004.
218. P LeCorre, RJ Parmer, MT Kailasam, BP Kennedy, TP Skaar, H Ho, R Leverge, DW Smith, MG Ziegler, PA Insel, NJ Schork, DA Flockhart, DT O'Connor. Human sympathetic activation by alpha--adrenergic blockade: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism. Clin Pharmacol Therap 139-153, 2004.
219. Tiffany A. Greenwood, Peter E. Cadman, Mats Stridsberg, Nicholas J. Schork, and Daniel T. O’Connor. Genome-wide Linkage Analysis of Chromogranin B Expression in the CEPH Pedigrees: Implications for Cardiovascular Physiology. Physiological Genomics 18: 119-127, 2004.
220. L Zhang, F Rao, J Wessel, BP Kennedy, BK Rana, L Taupenot, EO Lillie, NJ Schork, MG Ziegler, DT O’Connor. Functional allelic heterogeneity and pleiotropy of a repeat polymorphism in the tyrosine hydroxylase locus: Prediction of catecholamine secretion and cardiovascular response to stress in twins. Physiol Genomics 19:277-291, 2004.
221. Sushil K. Mahata, Gen Wen, Nitish Mahapatra, Manjula Mahata, Bruce A. Hamilton, and Daniel T. O’Connor. The catecholamine release-inhibitory “catestatin” fragment of chromogranin A: Naturally occurring human variants with different potencies to affect chromaffin cell secretory responses. Molecular Pharmacology 66:1180-91, 2004. 222. NR Mahapatra, M Mahata, P Hazra, P McDonough, DT O’Connor, SK Mahata.
A dynamic cellular pool of calcium in catecholamine storage vesicles: exploration in living cells by a novel vesicle-targeted chromogranin A/aequorin chimeric photoprotein. J Biol Chem 279:51107-21,2004 (co-corresponding author).
223. Phillips RA, Faulkner M, Gassman J, Jaen L, Kusek JW, Norris K, Ojo A.
O'Connor, Daniel T.
26
Recruitment of African Americans with chronic renal insufficiency into a multicenter clinical trial: for the African American Study of Kidney Disease and Hypertension Study Group. J Clin Hypertens (Greenwich). 2004 Aug;6(8):430-6.
224. HA Punzi, C F Punzi, and the Eprosartan Investigation Group. Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study. J Human Hypertension 2004;18(9):655-661.
2005 225. L Taupenot, KL Harper, DT O’Connor. Role of H+-ATPase-mediated
acidification in sorting and release of the regulated secretory protein chromogranin A: Evidence for a vesiculogenic function. J Biol Chem 280:3885-3897, 2005.
226. H Ho, A Pinto, SD Hall, DA Flockhart, L Li, T Skaar, P Cadman, DT O’Connor, U Wagner, NS Fineberg, MH Weinberger. Association Between CYP3A5 Genotype, Blood Pressure and Carbohydrate Intolerance. Hypertension, 45: 294-298, 2005.
227. RS Friese, P Mahboubi, NR Mahapatra, SK Mahata, NJ Schork, GW Schmid-Schönbein, DT O’Connor. Common genetic mechanisms of blood pressure elevation in two independent rodent models of human essential hypertension. Amer J Hypertension 18:633-52, 2005.
228. D King, JP Etzel, S Chopra, J Smith, PE Cadman, F Rao, BK Rana, NJ Schork, PA Insel, DT O’Connor. Human response to lpha 2-adrenergic agonist stimulation in an isolated vascular bed in vivo: biphasic influence of dose, age, gender, and receptor genotype. Clin Pharmacol Therap, 77:388-403, 2005.
229. Tang CM, Hoerning A, Buscher R, O'Connor DT, Ratjen F, Grasemann H, Insel PA. Human adenosine 2B receptor: SNP discovery and evaluation of expression in patients with cystic fibrosis. Pharmacogenet Genomics. 2005 May;15(5):321-327.
230. K Murthy, V Mahboubi, A.Santiago, MT Barragan, R Knoll, HP Schultheiss, DT O’Connor, NJ Schork, and BK Rana. Assessment of Multiple Displacement Amplification for Polymorphism Discovery and Haplotype Determination at a Highly Polymorphic Locus, MC1R. Human Mutation 26(2), 1-8, 2005.
231. Etzel, Jason; Rana, Brinda; Wen, Gen; Parmer, Robert; Schork, Nicholas; O’Connor, Daniel T. Genetic Variation at the Human α2B-Adrenergic Receptor Locus: Role in Blood Pressure Variation and Yohimbine Response. Hypertension. 2005; 45: 1207-1213.
232. Gabriel Contreras, Tom Greene, Lawrence Y. Agodoa, DeAnna Cheek, George Junco, Donna Dowie, James Lash, Michael Lipkowitz, Edgar R. Miller III, Akinlou Ojo, Mohammed Sika, Beth Wilkening, Robert D. Toto; for the African American Study of Kidney Disease and Hypertension (AASK) Study Group Investigators. Blood Pressure Control, Drug Therapy, and Kidney Disease. Hypertension, 46:44-50, 2005.
233. Daniel T. O'Connor, Peter E. Cadman, Clayton Smiley, Rany Salem, Fangwen Rao, Joshua Smith, Stephen D. Funk, Sushil K. Mahata, Manjula Mahata, Gen Wen, Laurent Taupenot, Carmen Gonzalez-Yanes, Kimberly L. Harper, Robert R. Henry, and Victor Sanchez-Margalet. Pancreastatin: Multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism. J Clin Endocrinol Metab 2005;90(9):5414-25.
234. Nitish R. Mahapatra*, Daniel T. O'Connor*, Sucheta Vaingankar*, Manjula Mahata, Eugenie Staite, Hongjiang Wu, Yusu Gu, Amiya P. Sinhahikim , Nancy Dalton , Brian P. Kennedy, Michael G. Ziegler, John Ross, and Sushil K. Mahata. Targeted ablation of the chromogranin A gene: rescue of the elevated blood
pressure by human homolog. J Clin Invest 115:1942-52, 2005 (co-first author).* 235. X Bao, PJ Mills, BK Rana, JE Dimsdale, Nicholas J Schork, DW Smith, F Rao, M
Milic, DT O’Connor, MG Ziegler. Interactive Effects of Common Beta-2-Adrenoceptor Haplotypes and Age on Susceptibility to Hypertension and Receptor Function. Hypertension 46:301-7, 2005.
236. BP Kennedy, F Rao, T Bottiglieri, S Sharma, EO Lillie, DT O’Connor. Contributions of the sympathetic nervous system, glutathione & body mass to BP
O'Connor, Daniel T.
27 27
increases with normal aging: influence of gender. J Hum Hypertension 19:951–969, 2005.
2006. 237. Nothacker HP, Wang Z, Zeng H, Mahata SK, O'Connor DT, Civelli O.
Proadrenomedullin N-terminal peptide and cortistatin activation of MrgX2 receptor is based on a common structural motif. Eur J Pharmacol. 2005 Sep 5;519(1-2):191-3.
238. F Rao, G Wen, S Mahata, B Kennedy, M Stridsberg, K Abel, D Smith, E Eskin, N Schork, B Hamilton, M Ziegler, DT O’Connor. The catecholamine release inhibitory peptide catestatin (chromogranin A [CHGA]352-372): A common naturally occurring variant (Gly364Ser) causes profound alterations in autonomic activity in humans. Circulation, acepted, 2006.
239. Rany M. Salem, Peter E. Cadman, Gen Wen, Brinda K. Rana, Fangwen Rao, E Eskin, Nicholas J. Schork, Mats Stridsberg, Harry J. Ward, Laurent Taupenot, and Daniel T. O’Connor. Polymorphisms at the Chromogranin A and B Loci are Risk Factors for Hypertensive End-stage Renal Disease in African Americans. Submitted (2006).
240. NR Mahapatra, M Mahata, SK Mahata, DT O’Connor. The chromogranin A fragment catestatin: specificity, potency, and mechanism to inhibit exocytotic secretion of multiple catecholamine storage vesicle co-transmitters. J Hypertension 24:895-904, 2006.
241. Riddle EL, Rana BK, Murthy KK, Rao F, Eskin E, O'Connor DT, Insel PA. Polymorphisms and Haplotypes of the Regulator of G Protein Signaling-2 Gene in Normotensives and Hypertensives. Hypertension 47:415-20, 2006.
242. TA Greenwood, F Rao, M Stridsberg, NR Mahapatra, M Mahata, EO Lillie, SK Mahata, L Taupenot, NJ Schork, DT O’Connor. Pleiotropic effects of novel trans-acting loci influencing human sympathochromaffin secretion. Physiol Genomics 25:470-9, 2006.
243. J Wessel, G Moratorio, F Rao, M Mahata, L Zhang, W Greene, BK Rana, BP Kennedy, S Khandrika, P Huang, EO Lillie, DW Smith, G Wen, BA Hamilton, MG Ziegler, JL Witztum, NJ Schork, GW Schmid-Schönbein, DT O’Connor. C reactive protein, an “intermediate phenotype” for inflammation: Human twin studies reveal heritability, association with blood pressure and the metabolic syndrome, and the influence of common polymorphism at catecholaminergic/e ta-adrenergic pathway loci. J Hypertension (in press, 2006).
244. TM Seasholtz, J Wessel, F Rao, BK Rana, S Khandrika, BP Kennedy, EO Lillie, MG Ziegler, DW Smith, NJ Schork, JH Brown, DT O’Connor. Rho kinase Polymorphism Influences Blood Pressure and Systemic Vascular Resistance in Human Twins: Role of Heredity. Hypertension 47:937-47, 2006.
245. F Rao, L Zhang, BP Kennedy, J Wessel, L Taupenot, G Wen, BK Rana, DW Smith, EO Lillie, PE Cadman, RM Salem, NJ Schork, MG Ziegler, DT O’Connor. Tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholamine biosynthesis: Discovery of common human genetic variants governing transcription, human autonomic activity and blood pressure in vivo. In revision at Circulation, 2006.
246. F Rao, J Wessel, G Wen, L Zhang, BK Rana, BP Kennedy, EO Lillie, RM Salem, BA Hamilton, DW Smith, N-H Holstein-Rathlou, MG Ziegler, NJ Schork, DT O’Connor. Renal albumin excretion, an “intermediate phenotype” for nephropathy: Human twin studies identify influences of heredity, environment, & the interactive role of polymorphism at adrenergic pathway loci. Hypertension (accepted, 2006).
247. Valle A, O’Connor DT, Taylor PW, Zhu G, Montgomery GW, Slagboom PE, Martin NG, Whitfield JB: Butyrylcholinesterase:Association with the metabolic syndrome and identification of two gene loci affecting activity. Clinical Chemistry 52:1014-20, 2006.
248. BK Rana, PA Insel, S Payne, K Abel, E Beutler, MG Ziegler, NJ Schork, DT O’Connor. Population-Based Sample Reveals Gene-Gender Interactions in Blood Pressure in White Americans. Hypertension 49:96-106, 2007.
249. EO Lillie, M Mahata, S Khandrika, F Rao, RA Bundey, G Wen, Y Chen, L Taupenot, DW Smith, SK Mahata, MG Ziegler, M Cockburn, NJ Schork, DT O’Connor. Heredity of endothelin secretion: Human twin studies reveal the influence of polymorphism at the chromogranin A locus, a novel determinant of endothelial function. Accepted at Circulation, 2006.
O'Connor, Daniel T.
28
250. Mahapatra NR, Mahata M, Ghosh S, Gayen JR, O'Connor DT, Mahata SK. Molecular basis of neuroendocrine cell type-specific expression of the chromogranin B gene: crucial role of the transcription factors CREB, AP-2, Egr-1 and Sp1. J Neurochem. 2006;99:119-33.
251. C Mosley, L Taupenot, N Biswas, JP Taulane, S Vaingankar, G Wen, NJ Schork, MG Ziegler, SK Mahata, DT O’Connor. Biogenesis of the secretory granule: Chromogranin A (CHGA) coiled-coil structure results in unusual physical properties and suggests a mechanism for granule core condensation. Submitted, Biochemistry, 2006.
252. DT O’Connor, G Zhu, F Rao, TA Greenwood, M Stridsberg, NG Martin, JB Whitfield. Heritability and genome-wide linkage in US and Australian twins identifies novel genomic regions controlling the catecholamine release-inhibitory peptide catestatin. Submitted.
253. L Zhang, F Rao, K Zhang, S Khandrika, M Das, SM Vaingankar, BP Kennedy, BK Rana, DW Smith, J Wessel, RM Salem, JL Rodroguez, SK Mahata, NJ Schork, MG Ziegler, DT O’Connor. GTP cyclohydrolase (GCH1), a rate-limiting enzyme in neurotransmitter biosynthesis: Discovery of common human genetic variants governing nitric oxide, autonomic activity, and cardiovascular risk in twin pairs. Submitted to J Clin Invest.
254. Courel M, Rodemer C, Nguyen ST, Pance A, Jackson AP, DT O’Connor, L Taupenot. Secretory granule biogenesis in sympathoadrenal cells: Identification of a granulogenic determinant in the secretory prohormone chromogranin A. J Biol Chem 2006;281(49):38038-51.
255. Gen Wen, Jennifer Wessel, Weidong Zhou, Georg B. Ehret, Fangwen Rao, Mats Stridsberg, Sushil K. Mahata, Peter M. Gent, Madhusudan Das, Richard S. Cooper, Aravinda Chakravarti, Huilin Zhou, Nicholas J. Schork, Daniel T. O’Connor, Bruce A. Hamilton. An ancestral SCG2 variant confers regulation by PHOX2 transcription factors and increased risk of hypertension. Submitted to Curr Biol, 2006.
II. Invited articles, book chapters, books. 1. O'Connor DT: Angiotensin-converting enzyme inhibition in renal hypertension
with captopril. In: Cardiovascular Medicine in the '80s: Angiotensin-Converting Enzyme Inhibition (JN Cohn, ed.). Biomedical Information Corp., New York, 1981. pp 78-83.
2. O'Connor DT, Duchin KL: Effect of nadolol on renal hemodynamics in patients with essential hypertension. In: The Haemodynamics of Nadolol, 2nd International Symposium (NK Hollenberg, ed.). Royal Society of Medicine nternational Congress and Symposium Series #51; Academic Press, Inc. (London) and Royal Society of Medicine, 1982. pp 10-16.
3. O'Connor DT, Stone RA: The renal kallikrein system: description and relationship to liver disease. In: The Kidney in Liver Disease (M Epstein, ed.). Elsevier, North Holland, 1983. pp 469-477.
4. O'Connor DT, Burton DG, Parmer RJ, Deftos LJ: Human chromogranin A: Detection by immunohistochemistry in C-cells and diverse polypeptide hormone producing tumors (Proceedings of the VIII International Conference on Calcium Regulating Hormones, Kobe, Japan, 1983). In: Endocrine Control of Bone and Calcium Metabolism (DV Cohn, T Fujita, JT Potts, RV Talmadge, ed.), Elsevier Science Publishers, BV, 1984. pp 187-190.
5. O'Connor DT: Radioimmunoassays of chromogranin. In: Krstulovic A (editor): Quantitative Analysis of Catecholamines and Related Compounds, Chapter 7. Ellis Horwood Ltd., Sussex, England, 1986. pp 302-315.
6. O'Connor DT: Review of The Kidney, vols. 1&2 (Brenner BM, and Rector FC, eds.). In: J Amer Med Assoc 256: 2740-1, 1986.
7. Parmer RJ, O'Connor DT: Central sympathetic agents in the treatment of hypertension. In: Contemporary Issues in Nephrology: Pharmacotherapy of Renal Diseases and Hypertension (WM Bennett, BM Brenner, JH Stein, eds.). Churchill-Livingston, New York, 1987. pp 255-27
O'Connor, Daniel T.
29 29
8. O'Connor DT, Deftos LJ: How senstive and specific is measurement of plasma chromogranin A for the diagnosis of neuroendocrine neoplasia? In: Cellular and Molecular Biology of Hormone and Neurotransmitter Containing Secretory Vesicles (RG Johnson, ed.). Ann NY Acad Sci 493: 379-386, 1987.
9. O'Connor DT: Review of: The adrenal medulla, volume 4 (by S.W. Carmichael). In: Psychoneuroendocrinology 12:407, 1987.
10. Cooper MJ, Helman L, Evans A, Swamy S, O'Connor DT, Helson L: Chromogranin A expression in childhood peripheral neuroectodermal tumors. Advances in Neuroblastoma 2: 175-184, 1988.
11. Takiyyuddin MA, Barbosa JA, Hsiao RJ, Parmer RJ, O'Connor DT: Diagnostic value of chromogranin A measured in the circulation. In: Markers for Neural and Endocrine Cells (Gratzl M and Langley K, eds.). VCH, New York, 1991. Chapter 6, pp. 191-201.
12. O'Connor DT, Takiyyuddin MA, Parmer RJ, Cervenka JH, Barbosa JA, Hsiao RJ, Chang YM: Sympathoadrenal catecholamine storage and release in man: insights from the study of chromogranin A. In: Neurobiology and Neuroendocrinology of Stress (Brown MR, Rivier C and Koob G, eds). Marcel Dekker, New York, 1991. Chapter 11, pp 217-29.
13. Rozansky DJ, O'Connor DT: Review of: Regulatory peptides in paraganglia (by C Heym and W Kummer). In: Psychoneuroendocrinology 14:403, 1989.
14. O'Connor DT, Takiyyuddin MA, Cervenka JH, Parmer RJ, Barbosa JA, Chang YM, Hsiao RJ: Circulating chromogranin A as a diagnostic tool in clinical chemistry. Acta Histochemica, Suppl.-Band XXXVIII, S. 27-33, 1990.
15. O'Connor DT: The wise for cure on exercise depend. (editorial) Circulation 83:1822-3, 1991.
16. Van Kammen DP, Peters JL, O'Connor DT, Gelernter J, Ekman R, Widerlov E, Guidotti A, Perel J, Kelley ME, Beuger M, Gurklis J: CSF peptides and long term neuroleptic treatment in schizophrenia: effects of haloperidol withdrawal and relapse. In: Biological Psychiatry, Volume 1 (G. Racagni et al, eds.). Elsevier Science Publishers B.V., 1991. pp. 580-2.
17. Kailasam MT, O'Connor DT, Parmer, RJ: The regulation and role of catecholamines in hypertension and pheochromocytoma. Current Opinion in Endocrinology and Diabetes 1:135-142, 1994.
18. O'Connor DT, Wu HJ, Gill BM, Rozansky DJ, Tang K, Mahata SK, Mahata M, Eskeland NL, Videen JS, Zhang X, Takiyyuddin MA, Parmer RJ: Hormone storage vesicle proteins: Transcriptional basis of the widespread neuroendocrine expression of chromogranin A, and evidence of its diverse biological actions, intracellular and extracellular. Ann NY Acad Sci 733:36-45, 1994.
19. Martinez JA, O'Connor DT: Somatic cell gene therapy for a trait as complex as hypertension? (editorial). J Clin Invest 95:1426, 1995.
20. Kailasam MT, O'Connor DT, Parmer RJ. Hereditary intermediate phenotypes in African American hypertension. Ethnicity and Health 1(2),133-144, 1996.
21. O'Connor DT: Adrenal medulla, catecholamines and pheochromocytoma. In: Cecil Textbook of Medicine published by W.B. Saunders. Editors: JC Bennett, F Plum. 20th edition, Chapter 204.2, pp. 1253-1257, 1996.
22. O'Connor DT, Kailasam MT, Parmer RJ. Complex Trait Genetics: New Methods Yield a Result for Essential Hypertension. (editorial) In: J Clin Invest, 97(9),1997-98, 1996.
23. Mahata SK, Mahata M, Yoo SH, Taupenot L, Wu HJ, Aroda V, Livsey CV, Taulane JP, Goodman M, Parmer RJ, O'Connor DT: A Novel, Catecholamine Release-Inhibitory
Peptide from Chromogranin A: Autocrine Control of Nicotinic Cholinergic-Stimulated Exocytosis. Advances in Pharmacology 42:206-4, 1998.
24. Kunau RT, Nasca TJ, Braun WE, Bushinsky DA, Faber MD, Hebert LA, Hou SH, Mehta R, O'Connor DT, Paller MS, Stivelman JC, Torres VE, Toto RD. 1998. Nephrology and Hypertension MKSAP (Medical Knowledge Self-Assessment
O'Connor, Daniel T.
30
Program), Second Edition, published by American College of Physicians/American Society of Internal Medicine.
25. L Taupenot, SK Mahata, H Wu, K Tang, M Mahata, RJ Parmer, DT O’Connor. Peptidergic stimulus-transcription coupling in chromaffin cells: regulation of chromogranin A gene expression by the neurotransmitter pituitary adenylyl cyclase-activating polypeptide (PACAP). Pp 249-259, in: The Adrenal Chromaffin Cell. Eds: T Kanno, Y Nakazato, K Kumakura. Hokkaido University Press, Sapporo, Japan, 1998, 394 pages.
26. O’Connor, Daniel T. Chromaffin cell mechanisms: understanding catecholamine storage and release. Trends in Pharmacolgical Sciences 20:431-432, 1999.
27. DT O’Connor, PA Insel, MG Ziegler, VY Hook, DW Smith, BA Hamilton, PW Taylor, RJ Parmer. Heredity and the Autonomic Nervous System in Human Hypertension. Current Hypertension Reports 2:16-22, 2000.
28. L Taupenot, Manjula Mahata, Sushil K. Mahata, Hongjiang Wu, and Daniel T. O'Connor. Regulation of Chromogranin A Transcription and Catecholamine Secretion by the Neuropeptide PACAP: Stimulation and Desensitization. Advances in Experimental Medicine and Biology, Vol 482, Chromogranins: Functional and Clinical Aspects, Chapter 7, pp 97-111, 2000.
29. Robert J. Parmer, Sushil K. Mahata, Qijiao Jiang, Laurent Taupenot, Yun Gong, Manjula Mahata, Daniel T. O'Connor, and Lindsey A. Miles. Tissue Plasminogen Activator and Chromaffin Cell Function. Advances in Experimental Medicine and Biology, Vol 482, Chromogranins: Functional and Clinical Aspects, Chapter 14, pp 179-192, 2000.
30. Sushil K. Mahata, Manjula Mahata, Carolyn V. Livsey Taylor, Laurent Taupenot, Robert J. Parmer, and Daniel T. O'Connor. The Novel Catecholamine Release Inhibitory Peptide Catestatin (Chromogranin A344-364): Properties and Function. Advances in Experimental Medicine and Biology, Vol 482, Chromogranins: Functional and Clinical Aspects, Chapter 21, pp 263-277, 2000.
31. Daniel T. O'Connor, Sushil K. Mahata, Laurent Taupenot, Manjula Mahata, Carolyn V. Livsey Taylor, Mala T. Kailasam, Michael G. Ziegler, and Robert J. Parmer. Chromogranin A in Human Disease. Advances in Experimental Medicine and Biology, Vol 482, Chromogranins: Functional and Clinical Aspects, Chapter 31, pp 377-388, 2000.
32. Timberlake, DS; O'Connor, DT; Parmer, RJ. Molecular genetics of essential hypertension: recent results and emerging strategies. Current Opinion in Nephrology and Hypertension 10(N1):71-79, 2001.
33. L Taupenot, DT O’Connor. Chromogranins/Secretogranins. In: Wiley Encyclopedia of Molecular Medicine, Vol 5, pp 772-779, 2002.
34. Daniel T. O’Connor, Lee E. Eiden (editors). The Chromaffin Cell: Transmitter Biosynthesis, Storage, Release, Actions, And Informatics. Ann NY Acad Sci, Volume 971:xv-659, 2002.
35. Daniel T. O’Connor. Preface. The Chromaffin Cell: Transmitter Biosynthesis, Storage, Release, Actions, And Informatics. In: The Chromaffin Cell: Transmitter Biosynthesis, Storage, Release, Actions, And Informatics. Eds: Daniel T. O’Connor and Lee E. Eiden. Ann NY Acad Sci 971:xv-xvi, 2002.
36. Sushil K. Mahata, Nitish R. Mahapatra, Manjula Mahata, Daniel T. O’Connor. Neuroendocrine cell type-specific and inducible expression of chromogranin/secretogranin genes: crucial promoter motifs. In: The Chromaffin Cell: Transmitter Biosynthesis, Storage, Release, Actions, And Informatics. Eds: Daniel T. O’Connor and Lee E. Eiden. Ann NY Acad Sci 971:27-38, 2002.
37. Xuping Bao, Brian Kennedy, Robert Enns, Manjula Mahata, Sushil Mahata, Daniel O’Connor, Michael G. Ziegler. A Truncated Mouse Phenylethanolamine
O'Connor, Daniel T.
31 31
N-methyltransferase Splice Variant with Dominant Negative Activity. In: The Chromaffin Cell: Transmitter Biosynthesis, Storage, Release, Actions, And Informatics. Eds: Daniel T. O’Connor and Lee E. Eiden. Ann NY Acad Sci 971:89-91, 2002.
38. Laurent Taupenot, Kimberly L. Harper, Nitish R. Mahapatra, Robert J. Parmer and Daniel T. O'Connor. Intracellular protein trafficking into catecholamine storage vesicles: novel chimeric photoproteins visualized by deconvolution fluorescence microscopy. In: The Chromaffin Cell: Transmitter Biosynthesis, Storage, Release, Actions, And Informatics. Eds: Daniel T. O’Connor and Lee E. Eiden. Ann NY Acad Sci 971:262-5, 2002.
39. Peter E. Cadman, Fangwen Rao, Sushil K. Mahata, and Daniel T. O’Connor. Studies of the Dysglycemic Peptide Pancreastatin Using a Human Forearm Model. In: The Chromaffin Cell: Transmitter Biosynthesis, Storage, Release, Actions, And Informatics. Eds: Daniel T. O’Connor and Lee E. Eiden. Ann NY Acad Sci 971:528-9, 2002.
40. Fangwen Rao, Harry R. Keiser, and Daniel T. O'Connor. Malignant and benign pheochromocytoma: chromaffin granule transmitters and the response to medical and surgical treatment. In: The Chromaffin Cell: Transmitter Biosynthesis, Storage, Release, Actions, And Informatics. Eds: Daniel T. O’Connor and Lee E. Eiden. Ann NY Acad Sci 971:530-2, 2002.
41. Daniel T. O’Connor, Mala T. Kailasam, Brian P. Kennedy, Michael G. Ziegler, Noboru Yanaihara, and Robert J. Parmer. The catecholamine release-inhibitory “catestatin” region of chromogranin A: early decline in humans at genetic risk of hypertension. In: The Chromaffin Cell: Transmitter Biosynthesis, Storage, Release, Actions, And Informatics. Eds: Daniel T. O’Connor and Lee E. Eiden. Ann NY Acad Sci 971:533-5, 2002.
42. PE Cadman, DT O’Connor. Pharmacogenomics of hypertension. Curr Opin Nephrol Hypertension 12:61-70, 2003.
43. Math P. Cuajungco, Yukio Ando, Felicia B. Axelrod, Italo Biaggioni, David Goldstein, Alan E. Guttmacher, Katrina Gwinn-Hardy, Maureen K. Hahn, Max J. Hilz, Giris Jacob, Jordan Jens, William R. Kennedy, Stephen B. Liggett, Daniel T. O’Connor, Sonia R. Peltzer, David Robertson, Beresh Y. Rubin, Quandra Scudder, Linda J. Smith, Gail E. Sonenshein, Jesper Q. Svejstrup, Yang Xu and Susan A. Slaugenhaupt. Hereditary Dysautonomias: Current Knowledge and Collaborations for the Future. Clin Autonom Research. 13:180-95, 2003.
44. O'Connor DT: Adrenal medulla, catecholamines and pheochromocytoma. Chapter 241 (pp 1419-1424), in: Cecil Textbook of Medicine, published by W.B. Saunders, Philadelphia. Editors: L Goldman and D Ausiello. 22nd edition, 2004.
45. C Smiley, S Chopra, DT O’Connor. Hypertension genetics: candidate genetic loci, “intermediate” phenotypes, and genome-wide searches for susceptibility loci. In: The Year In Hypertension, Chapter 7, pp153-172, 2004 (Nova).
46. RS Fries, F Rao, DT O’Connor. The adrenal medulla in hypertension. In: Molecular Mechanisms of Hypertension. JR Sowers, editor. Taylor and Francis, London, UK. Chapter 24, Pgs 1-8, 2006.
47. F Rao, R Friese, G Wen, L Zhang, L Taupenot, SK Mahata, MG Ziegler, DT O’Connor. Catecholamines, pheochromocytoma, and hypertension: genomic insights. In press, Comprehensive Hypertension, Elsevier, 2006 (Ed: E. Schiffrin).
48. K Zhang, F Rao, G Wen, L Taupenot, SK Mahata, DT O’Connor. Catecholamine storage vesicles and the metabolic syndrome: The role of the
O'Connor, Daniel T.
32
chromogranin A fragment pancreastatin. Diabetes, Obesity and Metabolism 8:621-633, 2006.
49. EO Lillie, DT O’Connor. Early phenotypic changes in hypertension: A role for the autonomic nervous system and heredity. Hypertension 2006;47:331-333.
III. Published abstracts. 1978 1. O'Connor DT, Eurman G, Frigon RP, Stone RA: Antihypertensive mechanisms
of chronic diuretic and propranolol therapy. Kidney Int 12: 471, 1978. Presented, ASN, 1977.
2. Preston RA, O'Connor DT, Mitas JA II, Stone RA: Effect of propranolol on baroreflex arc function in essential hypertension. Clin Res 26: 101A, 294A, 1978. Presented, AFCR, 1978.
3. O'Connor DT, Preston RA, Eurman G, Frigon RP, Stone RA: Involvement of the kallikrein-kinin system in the antihypertensive response to diuretic and propranolol therapy. Clin Res 26: 101A, 293A, 1978. Presented, AFCR, 1978.
4. Preston RA, O'Connor DT, Mitas JA II, Stone RA: Effects of chronic clonidine therapy on baroreflex sensitivity in essential hypertension. Clin Res 26: 293A, 1978; Kidney Int 14: 693, 1978.
5. Preston RA, O'Connor DT, Mitas JA II, Stone RA: Proposed mechanism of action of prazosin: effect on renal hemodynamics. Clin Res 26: 294A, 1978, Kidney Int 14: 774, 1978.
6. O'Connor DT, Preston RA, Stone RA: Thiazide induced increase in salt and water appetite is mediated by the renin angiotensin system, not by volume or osmolality. Kidney Int 14: 744, 1978.
7. O'Connor DT, Stone RA, Preston RA, Mitas JA, Wall J: Racial variation in the antihypertensive response to prazosin hydrochloride. Kidney Int 14: 657, 1978.
8. O'Connor DT, Preston RA, Stone RA: Thiazides diminish renal vascular resistance in essential hypertensive man. Kidney Int 14: 700, 1978, Clin Res 27: 17A, 316A, 1979. Presented, AFCR, 1979.
9. O'Connor DT, Grundy SM, Preston RA, Mitas JA II, Stone RA: Thiazides increase plasma cholesterol in essential hypertension. Kidney Int 14: 657, 1978; Clin Res 27: 48A, 1979.
10. O'Connor DT, Preston RA, Stone RA: Serum chloride as a determinant of thiazide induced increase in plasma renin activity. Kidney Int 14: 700, 1978.
11. Preston RA, O'Connor DT, Stone RA: Propranolol induced renal vasoconstriction: diminished renal perfusion and glomerular filtration. Kidney Int 14: 77, 1978; Clin Res 27: 17A, 469A, 1979. Presented, ASN, 1978.
12. Olshan A, O'Connor DT, Frigon RP, Stone RA: Furosemide antihypertensive effects are associated with the kallikrein-kinin system. Kidney Int 14: 701, 1978; Clin Res 27: 63A, 1979. Presented, AFCR, 1979.
13. Cohen IM, O'Connor DT, Preston RA, Frigon RP, Stone RA: Alteration of intrarenal hemodynamics during chronic sympatholytic therapy. Kidney Int 14: 754, 1978.
14. Cohen IM, O'Connor DT, Preston RA, Stone RA: Failure of chronic clonidine therapy to alter indices of sympathetic nervous system activity. Kidney Int 14: 648, 1978.
1979 15. Preston RA, O'Connor DT, Wall J, Stone RA: Vasodilator therapy and the renal
circulation: diminished afferent arteriolar resistance following prazosin therapy. Clin Res 27: 17A, 1979.
16. Cohen IM, Mitas JA, O'Connor DT, Preston RA, Stone RA: Antihypertensive mechanism of chronic clonidine therapy. Clin Res 27: 15A, 1979; Clin Res 27: 312A, 1979.
O'Connor, Daniel T.
33 33
17. Cohen IM, O'Connor DT, Preston RA, Frigon RP, Stone RA: Effect of clonidine on intrarenal hemodynamics. Clin Res 27: 60A, 1979.
18. Cohen IM, O'Connor DT, Stone RA: Antihypertensive superiority of guanabenz-hydrochlorothiazide combination over hydrochlorothiazide alone. Clin Res 27: 230A, 1979.
19. Barg A, O'Connor DT, Cervenka J, Sanfelippo M, Henderson L: Control of hypertension with hemofiltration. Kidney Int 16: 779, 1979; Clin Res 28: 61A, 1980.
20. Cohen IM, O'Connor DT, Skowsky R, Stone RA: Arginine vasopressin in essential hypertension: effects of prazosin therapy. Kidney Int 16: 904, 1979; Clin Res 28: 38A, 1980. Presented, AFCR, 1980.
21. Cohen IM, O'Connor DT, Skowsky R, Stone RA: The role of arginine vasopressin in essential hypertension. Kidney Int 16: 904, 1979.
22. Olshan AR, O'Connor DT, Cohen IM, Stone RA: An analysis of hypertension in adult onset diabetics. Kidney Int 16: 907, 1979.
23. O'Connor DT, Sasso E, Preston RA, Stone RA: Prazosin decreases baroreflex sensitivity in man. Kidney Int 16: 907, 1979; Clin Res 28: 38A, 1980.
24. Warren SE, Cohen IM, O'Connor DT, Cervenka J, Stone RA: Racial differences in response to guanabenz and hydrochlorothiazide. Kidney Int 16: 909, 1979; Clin Res 28: 19A, 1980.
25. Warren SE, Cohen IM, O'Connor DT, Cervenka J, Stone RA: Heterogeneity of renal hemodynamic response to captopril. Kidney Int 16: 909, 1979; Clin Res 28: 65A, 1980, Presented, AFCR, 1979.
26. Olshan AR, O'Connor DT, Cohen IM, Stone RA: Baroreflex dysfunction in adult onset diabetics with hypertension. Kidney Int 16: 922, 1979.
27. Warren SE, Cohen IM, O'Connor DT, Cervenka J, Stone RA: Mechanism of action of hydrochlorothiazide and guanabenz. Kidney Int 16: 924, 1979; Clin Res 28: 19A, 1980.
28. Mitas JA, Hedges JC, Peterson NR, O'Connor DT, Wilus PJ: Use of elevated urinary kallikrein excretion as a marker for nephrocarcinoma. Kidney Int 16: 934, 1979.
1980 29. Hsueh WA, Carlson EJ, O'Connor DT, Warren SE: Evidence that a structural
alteration of renin is required for its activation by kallikrein. Clin Res 28: 331A, 1980.
30. O'Connor DT, Barg AP, Cervenka J: Propranolol effects on sodium and volume homeostasis in essential hypertension: enhanced fractional sodium excretion despite diminished glomerular filtration rate and urinary kallikrein excretion. Clin Res 28: 355A, 1980.
31. Warren SE, O'Connor DT, Stone RA: Mechanism of blood pressure reduction during sodium restriction in hypertensive man. Clin Res 28: 337A, 1980.
32. Warren SE, O'Connor DT, Stone RA: Sympathetic nervous activity during dietary sodium depletion in hypertension. Clin Res 28: 337A, 1980.
33. Warren SE, O'Connor DT, Cohen IM, Cervenka J: Captopril alters autonomic function in hypertensive man. Circ 62(Suppl. III): III89, 1980; Clin Res 29: 24A, 1981; Presented, AFCR, 1981.
1981 34. Zager PG, Hsueh WA, Leutscher JA, O'Connor DT, Warren SE: Defect in
conversion of inactive renin to active renin in diabetic subjects with nephropathy and hyperkalemia. Kidney Int 19:178, 1981.
35. Warren SE, O'Connor DT, Cervenka J: Racial differences during chronic prazosin therapy of hypertension. Kidney Int 19: 177, 1981.
36. Warren SE, O'Connor DT, Levine GL: Dopamine-beta-hydroxylase measurements and myocardial function. Kidney Int 19: 177, 1981.
37. Barg A, Vincente F, Amend W, O'Connor DT: Urinary kallikrein after renal transplantation: findings in hypertensive versus normotensive graft recipients;
O'Connor, Daniel T.
34
living related donor vs. cadaveric grafts; and acute rejection vs. acute tubular necrosis. Kidney Int 19: 163, 1981; Clin Res 29: 71A, 1981.
38. O'Connor DT, Frigon RP: Human chromogranin A: the major catecholamine storage vesicle protein. Clin Res 29: 44A, 359A, 1981; Presented, AFCR, 1981.
39. Griswold WR, Brams M, O'Connor DT, Reznick V, Mendoza SA: Captopril therapy in severe childhood hypertension. Clin Res 29: 121A, 1981.
40. Sokoloff RL, O'Connor DT, Frigon RP: Chromogranins A, B, and C of the cow and human: comparisons. Fed Proc 40: 1842, 1981; Presented, Am Soc Biol Chem, 1981.
41. Foote SL, Morrison JH, Bloom FE, O'Connor DT: Laminar and regional distribution of norepinephrine fibers in squirrel monkey neocortex as revealed by immunohistochemistry. Soc Neuro Abstr 7: 792, 1981.
1982 42. O'Connor DT, Mosely C, Cervenka J, Taylor A, Slutsky R: Guanabenz
selectively reduces renal vascular resistance in essential hypertension. Kidney Int 21:191, 1982; Presented, ASN, 1981.
43. Henderson LW, Barg AP, Sanfelippo ML, O'Connor DT: Changes of precapillary resistance with hemofiltration in the maintenance dialysis patient with hypertension. Kidney Int 21: 188, 1982.
44. O'Connor DT, Shoemaker W, Frigon RP, Azad R, Bloom F: Enkephalins in human pheochromocytoma: localization with catecholamines in catecholamine storage vesicles. Clin Res 30: 50A, 338A, 1982. Presented AFCR, 1982.
45. O'Connor DT, Gochman N: Lactate dehydrogenase activity in human pheochromocytoma: serum elevation, isoenzyme pattern and tissue source. Clin Res 30: 50A, 1982.
46. O'Connor DT, Frigon RP: A radioimmunoassay for bovine chromogranin A. Clin Res 30(2): 338A, 1982.
47. Duchin KL, O'Connor DT, Barg AP: Chronic effects of oral nadolol on renal hemodynamics in essential hypertension. J Clin Pharmacol 22(4) (suppl.): 6A, 1982.
48. Gozes I, O'Connor DT, Bloom FE: Sequestering of vasoactive intestinal polypeptide in pheochromocytoma chromaffin granules: a possible high molecular weight precursor. Soc Neurosci Abstr 8: 1982.
1983 49. O'Connor DT, Frigon RP: Enkephalins in human pheochromocytoma:
subcellular storage in and release from catecholamine storage vesicles and generation from precursors by controlled proteolysis. Kidney Int 23: 174, 1983; Presented, ASN, 1982.
50. Bernstein KN, Barg AP, Cervenka J, O'Connor DT: Sympatholytic effect of a non-CNS penetrating beta blocker in hypertension is unmasked by parasympathetic inhibition. Kidney Int 23: 167, 1983; Presented, ASN, 1982.
51. O'Connor DT: Chromogranin A: the major soluble protein of adrenal medullary catecholamine storage vesicles: Ubiquitous occurrence in polypeptide hormone producing tissues derived from neural crest. Clin Res 31: 25A, 275A, 1983; Fed Proc 42: 381, 1983; Presented, AFCR, 1983.
52. O'Connor DT, Levine GL, Frigon RP: Elevated cerebrospinal fluid dopamine-beta-hydroxylase by radioimmunoassay in human hypertension. Clin Res 31: 42A, 333A, 1983; Presented, AFCR, 1983.
53. Parmer R, Mosley C, O'Connor DT: Enkephalins in pheochromocytoma: Studies in a rat model. Clin Res 31(2): 333A, 1983; Presented, AFCR, 1983.
54. Bernstein KN, Mosley C, O'Connor DT, Cervenka J: Enalapril (MK-421) an angiotensin converting enzyme inhibitor: effects on sympathetic nervous system function during treatment of hypertension. Clin Res 31(2): 246A, 1983.
55. Snavely MD, Mahan LC, O'Connor DT, Insel PA: Adrenergic receptor subtypes are selectively down regulated in pheochromocytoma. Clin Res 31(2): 254A, 1983.
O'Connor, Daniel T.
35 35
1984 56. O'Connor DT, Klein RL: Chromogranin A: presence in large dense core
catecholamine storage vesicles of sympathetic nerve. Clin Res 32(2): 336A, 1984; Presented, AFCR, 1984.
57. O'Connor DT, Burton DG, Deftos L: Chromogranin A, the major catecholamine storage vesicle soluble protein: immunohistology reveals a widespread occurrence in normal polypeptide hormone producing tissues. Kidney Int 25(1): 204, 1984; Presented, ASN, 1984.
58. O'Connor DT: Human plasma chromogranin A: Detected by radioimmunoassay and elevation in pheochromocytoma and in essential hypertension. Clin Res 32(2): 336A, 1984; Presented, AFCR, 1984.
59. O'Connor DT, Deftos LJ: Human chromogranin A: Radioimmunoassay demonstrates diagnostic plasma elevations in diverse peptide producing tumors. Clin Res 32(2): 547A, 1984; Presented, AFCR, 1984.
1985 60. O'Connor DT, Sokoloff RL: Dopamine-beta-hydroxylase: is there a structural
difference between soluble and membrane-bound DBH forms in catecholamine storage vesicles of bovine adrenal medulla or human pheochromocytoma? Clin Res 33(2): 367A, 1985; Presented, AFCR, 1985.
61. Mezger MS, O'Connor DT: Electrostatic interaction between Ca2+ and adrenal catecholamine storage vesicle soluble proteins (chromogranins). Clin Res 33(2): 365A, 1985; Presented, AFCR, 1985.
1986 62. Mezger MS, O'Connor DT: Plasma chromogranin A in subjects with renal
failure: elevation proportional to degree of renal failure and retention of immunoreactive fragments. Kidney Int 29(1): 198, 1986.
63. Parmer RJ, O'Connor DT: Renal hemodynamic stability after converting enzyme inhibition in renovascular hypertension. Kidney Int 29(1): 255, 1986; Presented, ASN, 1985.
64. O'Connor DT, Deftos LJ: How sensitive and specific is measurement of plasma chromogranin A in diagnosis of neuroendocrine neoplasia? Clin Res 34: 551A, 1986; Presented, AFCR, 1986.
1987 65. O'Connor DT, Pandian MR, Cervenka J, Mezger M, Parmer RJ: What is the
source and disposition of chromogranin A in normal human plasma? Clin Res 35: 605A, 1987; Presented, AFCR, 1987.
66. Parmer RJ, O'Connor DT: Sympathetic nervous system activity in hypertension: Are there racial differences? Kidney Int 30: 306, 1987; Presented, ASN, 1986.
67. O'Connor DT, Mezger M, Chang Y-M: Catecholamines interact with chromogranins, the major catecholamine storage vesicle soluble core proteins. Kidney Int 30: 305, 1987; Presented, ASN, 1986.
1988 68. O'Connor DT, Subramani S: Do transcriptional enhancers also augment DNA
replication? Clin Res 36(1): 184A, 1988; Presented, AFCR, 1988. 69. O'Connor DT, Takiyyuddin M: Synthetic peptide epitopes: clues to the structure,
conformation, distribution and processing of chromogranin A (CgA). Clin Res 36(1): 187A, 1988; Am J Htn 1:52A, 1988. Presented, ASH, 1988.
70. Takiyyuddin M, Cervenka J, Kennedy B, Stuenkel C, O'Connor DT: Pulsatile release of plasma chromogranin A in man. Am J Hypertension 1:43A, 1988. Presented, ASH, 1988.
O'Connor, Daniel T.
36
71. Parmer RJ, Koop AJ, Handa M, O'Connor DT: Molecular cloning of chromogranin A from a rat pheochromocytoma cDNA library provides insight into functional domains. Am J Htn 1:65A, 1988. Presented, ASH, 1988.
72. Takiyyuddin M, Cervenka J, Pandian MR, O'Connor DT: Selective adrenal medullary stimulation releases chromogranin A in man. Am J Htn 1: 52A, 1988. Presented, ASH, 1988.
73. Wu HJ, Parmer RJ, Koop AH, O'Connor DT: Molecular cloning of a dopamine-beta-hydroxylase cDNA. Am J Htn 1: 65A, 1988. Presented, ASH, 1988.
1989 74. Takiyyuddin M, Sullivan P, Cervenka J, O'Connor DT: Exocytotic catecholamine
and chromogranin A (CgA) corelease during selective stimulation of the sympathetic nervous system (SNS) in man. Presented, Am Soc Nephrol, 1988. Kidney Int 35:335, 1989.
75. O'Connor DT, Neumann HPH: Chromogranin A (CgA) disposition and distribution in man: Insights from CgA kinetics after resection of pheochromocytoma (pheo). Presented, Am Soc Nephrol, 1988. Kidney Int 35: 333, 1989.
76. Wu HJ, Parmer RJ, Koop AH, Rozansky DJ, O'Connor DT. Dopamine-beta-hydroxylase (DBH): a cDNA clone illuminates structural domains. Presented, ASCB/ASBMB, 1988-9. Abstracts p. 507a, 1989.
77. O'Connor DT, Cervenka JH, Parmer RJ. Chromogranin A (CgA): Specific detection in human cerebrospinal fluid (CSF). Clin Res 37(1): 162A, 1989.
78. Hsiao RJ, Neumann HPH, Takiyyuddin MA, O'Connor DT. Chromogranin A (CgA) in familial pheochromocytoma (pheo): Diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution. Clin Res 37(1): 156A, 1989. Presented, WSCI, 1989.
79. Peirce J, Gill B, DeGuire M, Dinh T, Garrod S, O'Connor DT: Secretory vesicle processing of chromogranin A (CgA). Presented to FASEB annual meeting, 1989.
80. Takiyyuddin MA, Cervenka J, Baron AD, O'Connor DT: Somatostatin (SRIF) suppresses the pulsatile release of chromogranin A (CgA) in man. Presented, AFCR National Meeting, 1989. Clin Res 37(2): 461A, 1989.
81. Takiyyuddin MA, Sullivan P, Cervenka J, Brown M, O'Connor DT: Postexercise increase in plasma neuropeptide-Y (NPY) and norepinephrine (NE). Presented, AFCR National Meeting, 1989. Clin Res 37(2): 301A, 1989.
82. Hsiao RJ, Seeger RC, O'Connor DT: Chromogranin A (CgA) in children with neuroblastoma (NB): Plasma concentration parallels disease stage and predicts survival. Presented, AFCR National Meeting, 1989. Clin Res 37(2): 576A, 1989.
83. Polikar R, Kennedy B, Ziegler M, O'Connor DT, Smith J, Maisel A, Nicod P: Norepinephrine plasma kinetics in hypothyroid patients before and following replacement therapy. Presented, ASCI National Meeting, 1989. Clin Res 37(2): 362A, 1989.
84. Carmichael SW, Tyce GM, Yaksh TL, O'Connor DT, Stoddard SL: Secretion of catecholamines, neuropeptide Y, and chromogranin A from the adrenal medulla via venous and lymphatic routes. 12th Meeting Int Soc for Neurochemistry, Algarve, Portugal, 1989. J Neurochem 52:S87, 1989.
85. Barbosa JA, Gill BM, Hsiao RJ, Garrod S, O'Connor DT: Human chromogranin A: synthetic peptide reagents, preparative electrophoresis, and microsequencing demonstrate multiple post-translational modifications. Presented, ASN, 1989. Kidney International 37: 382, 1990.
86. Takiyyuddin MA, Barbosa JA, Casto RL, Printz MP, O'Connor DT: Augmented storage and release of a catecholamine storage vesicle protein in genetic hypertension. Presented, ASN, 1989. Kidney International 37: 394, 1990.
87. Parmer RJ, Wood PJ, O'Connell N, O'Connor DT: Chromogranin A in the evaluation of hypercalcemia. Submitted, ASN, 1989. Kidney International 37: 469, 1990.
O'Connor, Daniel T.
37 37
88. O'Connor DT, Takiyyuddin MA, Parmer RJ, Hsiao RJ, Cervenka JH, Gill BM, Barbosa JA: Chromogranin A and the adrenal medulla in hypertension. Presented, 5th International Symposium on Chromaffin Cell Biology, Jerusalem, Israel, May 1989. Abstracts, page 58. Presented (plenary lecture), ASH, 1989.
1990 89. Hsiao RJ, Parmer RJ, Takiyyuddin MA, O'Connor DT: Chromogranin A: Can it
identify pheochromocytoma in human hypertensive populations? Presented, WSCI, Carmel, CA, February 1990. Clin Res 38: 151A, 1990.
90. Parmer RJ, Stone RA, Cervenka JH, O'Connor DT: Baroreflex sensitivity in human hypertension is genetically determined. Presented ASCI, 1990. Presented, International Society of Hypertension, Montreal, 1990. Presented, ASN, 1990. Clin Res 38(2): 476A, 1990. J Am Soc Nephrol 1(4):510, 1991.
91. Takiyyuddin MA, Cervenka JH, Barbosa JA, Parmer RJ, O'Connor DT: Exaggerated exocytotic adrenal medullary activity in response to stress in essential hypertension. Presented, ASCI, 1990. Clin Res 38(2): 477A, 1990.
92. Takiyyuddin MA, Cervenka JH, Barbosa JA, Hsiao RJ, O'Connor DT: Pharmacologic dissociation of chromogranin A and catecholamines in man. Clin Res 38(2): 522A, 1990.
93. Takiyyuddin MA, Barbosa JA, Casto RL, Printz MP, O'Connor DT: Overexpression of chromogranin A: a Mendelian trait that cosegregates with genetic hypertension. ASN, 1990. JASN 1(4):501, 1991.
94. Ford N, Natarajan C, Much D, Nichola P, Emans N, Swanson B, Cutler R, O'Connor DT, Sica D: Steady-state pharmacokinetics of fosinopril, enalapril, and lisinopril in patients with chronic renal insufficiency. ASN, 1990. JASN 1(4):323, 1991.
1991 95. Dimsdale JE, O'Connor DT, Ziegler M, Mills P: Chromogranin and sympathetic
nervous system differences between blacks and whites. Presented, ASH, 1991. Am J Htn 4(5):78A, 1991.
96. Parmer RJ, Petz LN, Rietow MG, Helman LJ, O'Connor DT: Human chromogranin A is targeted to and released from regulated secretory vesicles in rat pheochromocytoma cells. Presented, ASCI, 1991. Winner of the Henry Christian Award for Clinical Research, AFCR, 1991. Clin Res 39(2):172A, 1991.
97. Takiyyuddin MA, DeNicola L, Kennedy B, Dinh TQ, Gabbai FB, Ziegler MG, O'Connor DT: Upregulation of a catecholamine storage vesicle protein in two-kidney, one clip hypertension. Submitted, AFCR, 1991. Clin Res 39(2):433A, 1991. Presented, American Heart Association Council for High Blood Pressure Research, September, 1991. Hypertension 18(3):417, 1991.
98. Rozansky DJ, Wu HJ, Parmer R, O'Connor DT: Identification of 5' regulatory region for the rat chromogranin A gene. Presented, ASCI, 1991. Clin Res 39(2):350A, 1991.
99. Wu HJ, Rozansky DJ, Parmer RJ, Gill BM, O'Connor DT: Structure of the mouse chromogranin A gene and tissue specificity of its promoter. Presented, ASCI, 1991. Clin Res 39(2):365A, 1991.
100. Videen JS, O'Connor DT: Interactions of cations and proteins in catecholamine storage vesicles. Presented, ASCI, 1991. Clin Res 39(2):365A, 1991.
101. Parmer RJ, Stone RA, Cervenka JH, O'Connor DT: Renal hemodynamics in essential hypertension: racial differences in response to dietary salt. Presented, ASN, 1991. JASN 2(3):493, 1991.
1992 102. Sullivan PA; Grosch C, Lawless D, O'Connor DT: Short-term strenuous
exercise training: effects on blood pressure and hormonal levels in mild hypertension. Ir-J-Med-Sci. 1992 Dec; 161(12):666-9.
O'Connor, Daniel T.
38
1993 103. Kailasam MT, Lin MC, Cervenka JH, Parmer RJ, O'Connor DT: Effects of an
oral prostaglandin E, agonist on blood pressure and its determinants in essential hypertension. Hypertension 21(4):582, 1993. Presented, 10th Scientific Meeting, IASH, La Jolla, April, 1993.
104. Parmer RJ, O'Connor DT, Xi XP, Wu HJ, Fowler B, Miles LA: Rat pheochromocytoma cells express mRNA and binding sites for plasmin(ogen) to promote processing of chromogranin A (CgA), the major soluble protein in catecholamine storage vesicles. Hypertension 21(4):555, 1993. Presented, 10th Scientific Meeting, IASH, April 1993.
105. Garcia GE, Gabbai FB, O'Connor DT, Dinh TQ, Kennedy B, Ziegler MG, Takiyyuddin MA: Chromostatin (chromogranin A) does not diminish catecholamine release or blood pressure in vivo. Hypertension 21(4):535, 1993. Presented, 10th Scientific Meeting, IASH, April 1993.
106. Tang K, Wu HJ, Cowles C, O'Connor DT: Stimulus transcription (stimulus-secretion-synthesis) coupling in chromaffin cells. Hypertension 21(4):543, 1993. Presented, 10th Scientific Meeting, IASH, April 1993; ASBMB, San Diego, May, 1993.
107. Parmer RJ, Cervenka JH, Kailasam MT, O'Connor DT: Blood pressure fall in response to exogenous nitric oxide: A bimodally distributed phenotype suggesting Mendelian inheritance in human essential hypertension. Presented, AHA Council for High Blood Pressure Research, September 1993. Hypertension 22(3):407, 1993.
108. Wu HJ, Parmer RJ, O'Connor DT: Cell type-specific expression of a sympathochromaffin gene: studies of the chromogranin A promoter. Presented, AHA Council for High Blood Pressure Research, September, 1993. Hypertension 18(3):423, 1993.
1994 109. Dao TT, Kailasam MT, Cervenka JH, Parmer RJ, O'Connor, DT. Early
expression of altered alpha-2-adrenergic phenotypic traits ("Intermediate phenotypes") in humans at genetic risk of essential hypertension. Presented at the 48th Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research, 1994. Hypertension (Dallas), v.24, n.3, :400, 1994.
110. Kailasam MT, Parmer RJ, Cervenka JH, O'Connor DT: Differential effects of calcium channel blockers on baroreflex and sympatho-adrenal activity in essential hypertension. Presented, 9th Scientific Meeting, ASH, May 1994. Amer J Hypertension 7(4)2:136A, 1994.
111. Kailasam MT, Brinton TJ, Wu RA, Hu G, Chio S-S, Cervenka JH, Parmer RJ, O'Connor DT: Non-invasive waveform analysis in hypertension: development of the method, and early compliance changes in subjects at genetic risk of hypertension. Presented, 9th Scientific Meeting, ASH, May 1994. Amer J of Hypertension 7(4)2:86A, 1994.
112. Parmer RJ, Mahata M, Mahata SK, O'Connor DT, Miles, L: Storage and secretion of tissue plasminogen activator (t-PA) by catecholamine storage vesicles (CSV): A reservoir for the acute release of t-PA. Presented, 27th Annual Meeting, ASN, Oct 1994. JASN (5) 3:548, 1994.
113. Parmer, Robert J., Kailasam, Mala T., Dao, T. Teresa, Cervenka, Justine H., Kennedy, Brian, Ziegler, Michael G., O'Connor DT. Alpha-2-Adrenergic
regulation of blood pressure: Racial differences. Abstracts Submitted for the 27th Annual Meeting of the American Society of Nephrology, 1994. Journal of the American Society of Nephrology, v.5, n. 3:565, 1994. Presented, 27th Annual Meeting, ASN, Oct 1994. JASN (5)3:565, 1994. Presented, AHA Council for High Blood Pressure Research, 48th Annual Fall Conference and Scientific Sessions, Sep 1994. Hypertension 24(3):378, 1994.
114. Parmer RJ, O'Connor DT, Miles LA. Role of the cell surface fibrinolytic system in processing of the chromaffin granule protein, chromogranin A (CgA).
O'Connor, Daniel T.
39 39
Presented at the XIIth International Congress on Fibrinolysis, 1994. Fibrinolysis, v.8, n.SUPPL. 1, 1994.:53.
115. Rozansky D, Wu HJ, Tang K, Parmer RJ, O'Connor DT. Glucocorticoid activation of chromogranin A gene expression: characterization of a novel glucocorticoid response element. Presented, AHA Council for High Blood Pressure Research, September 1994. J Clin Invest 94:2357-2368, 1994.
1995 116. Dao TT, Kailasam MT, Cervenka JH, Parmer RJ, O'Connor DT: Early
expression of altered alpha-2--adrenergic phenotypic traits ("intermediate phenotypes") in humans at genetic risk of essential hypertension. Presented, AHA Council for High Blood Pressure Research, 48th Annual Fall Conference and Scientific Sessions, Sep 1994. Hypertension 24(3):400, 1994. Presented, AFCR Western Section Meeting, 1995. J of Investigative Medicine 43(1):167A, 1995.
117. Martinez JA, Dao TT, Kailasam MT, Parmer RJ, O'Connor DT: Renal kallikrein excretion: early changes in subjects at genetic risk for essential hypertension. Presented, AFCR Western Section Meeting, 1995. J of Investigative Medicine 43(1):166A, 1995.
118. Kailasam MT, Fineman MS, Koda JE, Parmer RJ, O'Connor DT: Circulating amylin in human essential hypertension: racial differences and early elevations in subjects at genetic risk of hypertension. Presented, AFCR Clinical Research Meeting, 1995. J of Investigative Medicine 43(2):266A, 1995.
119. Tang K, Wu HJ, Rozansky DJ, Parmer RJ, O'Connor DT. Stimulus-transcription coupling in chromaffin cells: promoter region-specific activation of catecholamine storage vesicle peptide biosynthesis. Presented, AHA Council for High Blood Pressure Research, September, 1995. Hypertension 26(3):544, 1995.
120. Wu HJ, Mahata SK, Mahata M, Webster NJG, Parmer RJ, O'Connor DT. A functional cAMP response element (CRE) plays a crucial role in neuroendocrine (NE)-specific expression of the catecholamine secretory granule protein, chromogranin A (CgA). Presented, AHA Council for High Blood Pressure Research, September, 1995. Hypertension 26(3):548, 1995.
121. Parmer RJ, Kailasam MT, Martinez JA, Wright FA, Wilson AF, O'Connor DT. Evidence suggesting that urinary kallikrein excretion is heritable in African American families with essential hypertension. Presented, AHA Council for High Blood Pressure Research, September, 1995. Hypertension 26(3):545, 1995. Journal of the American Society of Nephrology, v.6, n.3, 1995.:647. Conference: Annual Meeting of the American Society of Nephrology.
122. Mahata, M.; Mahata, S. K.; Satriano, J.; O'Connor, D. T.; Parmer, R. J. The arginine (ARG) metabolite agmatine (AGM) is a non-competitive nicotinic cholinergic antagonist which inhibits catecholamine secretion. Journal of the American Society of Nephrology, v.6, n.3, 1995.:627. Conference: Annual Meeting of the American Society of Nephrology
1996 123. Hocker, Michael; Wu, Hongjiang; Nicholls, Patrick; O'Connor, Daniel T.; Wang,
Timothy C. The mouse chromogranin a promoter is regulated by gastrin through an upstream GC-rich sequence. Gastroenterology, v.110, n.4 SUPPL., 1996.:A1081. Conference: 96th Annual Meeting of the American Gastroenterological Association and the Digestive Disease Week.
124. Kong, C.; Gill, B. M.; Rahmipour, R.; Xu, L.; Feldman, R.; O'Connor, DT.; Kelvin, D. J. Secretoneurin (SN) induces monocyte chemotaxis through a pertussis toxin-(PT) signaling pathway. FASEB Journal, v.10, n.6, 1996.:A1074. Conference: Joint Meeting of the American Society for Biochemistry and Molecular Biology, the American Society for Investigative Pathology and the
O'Connor, Daniel T.
40
American Association of Immunologists. 125. Le H, Kailasam MT, Cervenka JH, Wilson AF, and O'Connor DT and Parmer
RJ. Sympathetic nervous system reactivity to cold stress in families with essential hypertension: Racial differences and evidence for heritability. Journal of the American Society of Nephrology, v.7, n.9, 1996:1552. Presented at the 29th ASN Annual Meeting in New Orleans, LA. November 3-6, 1996.
126. Parmer RJ, Le H, Kailasam MT, Wilson AF, and O'Connor DT. Impaired Baroreflex sensitivity is associated with blood pressure elevation and dyslipidemia in families with essential hypertension. Journal of the American Society of Nephrology, v.7, n.9, 1996:1554. Presented at the 29th ASN Annual Meeting in New Orleans, LA. November 3-6, 1996. Hypertension (Dallas), v.28, n.3, 1996.:509. Conference: 50th Annual Conference and Scientific Sessions of the Council for High Blood Pressure Research.
127. Parmer, R. J.; Mahata, M.; Mahata, S.; Sebald, M. T.; O'Connor, DT.; Miles, L. A.. Tissue plasminogen activator (t-PA) is targeted to the regulated secretory pathway: Catecholamine storage vesicles as a reservoir for the rapid release of t-PA. Fibrinolysis, v.10, n.SUPPL. 3, 1996.:86. Conference: XIIIth International Congress on Fibrinolysis and Thrombolysis.
181. Wong CM, O'Connor DT, Martinez JA, Parmer RJ. Dysregulation of renal kallikrein responses to mineralocorticoid secretagogues in African-Americans. Journal of the American Society of Nephrology, v.7, n.9, 1996.:1557. Presented at the 29th ASN Annual Meeting in New Orleans, LA. November 3-6, 1996.
1997 129. Cubells, J. F.; Van Kammen, D. P.; Rao, P.; Kelley, M. E.; O'Connor, DT;
Gelernter, J. CSF levels of dopamine beta-hydroxylase protein and alleles of the DBH gene in schizophrenic subjects. Society for Neuroscience Abstracts, v.23, n.1-2, 1997.:556. Conference: 27th Annual Meeting of the Society for Neuroscience, Part 1. American Journal of Human Genetics, v.61, n.4 SUPPL., Oct., 1997.:A272. Conference: 27th Annual Meeting of the Society for Neuroscience, Part 1.
130. Hoecker, Michael; Waigand, K.; Rosewicz, S.; O'Connor, DT; Riecken, E. O.; Wiedenmann, B.; Wang, T. C.. Gastrin regulates chromogranin A promoter activity in AGS-B gastric carcinoma cells and transgenic mice. Gastroenterology, v.112, n.4 SUPPL., 1997.:A1155. Conference: Digestive Disease Week and the 97th Annual Meeting of the American Gastroenterological Association.
131. Kailasam, T.; Martinez, Joseph A.; Cervenka, Justine H.; Yen, Samuel S. C.; O'Connor, Daniel T.; Parmer, Robert J.. Racial differences in renal kallikrein excretion in ovulating females. Journal of the American Society of Nephrology, v.9, n.PROGRAM AND ABSTR. ISSUE, Sept., 1997.:317A. Conference: 30th Annual Meeting of the American Society of Nephrology Pub type: BOOK; CONFERENCE LITERATURE; CHAPTER.
132. Shen, Guoqiu; Trejo, Devin; Wu, Nancy; Lal, Navanit; O'Connor, DT. Comparison of native and recombinant chromogranin A antigens. Journal of the American Society of Nephrology, v.9, n.PROGRAM AND ABSTR. ISSUE, Sept., 1997.:395A. Conference: 30th Annual Meeting of the American Society of Nephrology.
1998 133. Hoecker, Michael; Raychowdury, Raktima; Plath, Thoams; Wu, Hongjiang;
O'Connor, Daniel T.; Wiedenmann, Bertram; Rosewicz, Stefan; Wang, Timothy C.. Sp1 and CREB mediate gastrin-dependent regulation of chromogranin A
O'Connor, Daniel T.
41 41
promoter activity. Digestive Diseases and Sciences, v.43, n.8, Aug., 1998.:1895. Conference: 12th International Symposium on Regulatory Peptides. Gastroenterology, v.114, n.4 PART 2, April 15, 1998.:A1150. Conference: Digestive Diseases Week and the 99th Annual Meeting of the American Gastroenterological Association.
134. Kailasam, Mala T.; Diggle, Karin; Wilson, Alexander F.; O'Connor, Daniel T.; Parmer, Robert J. Linkage of alpha-adrenergic pressor responsiveness to chromosome 5q in hypertensive families. Journal of the American Society of Nephrology, v.9, n.PROGRAM AND ABSTR. ISSUE, Sept., 1998.:325A. Conference: 31st Annual Meeting of the American Society of Nephrology. Hypertension (Dallas), v.32, n.3, Sept., 1998.:593. Conference: 52nd Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research.
135. Lewis, J.B.; Agodoa, L.; Cheek, D.; Greene, T.; Middleton, J.; O'Connor, D.; Wright, J.; (USA), AASK Study Group. Estimation of GFR from serum creatinine in the African-American study of kidney disease and hypertension (AASK). Journal of the American Society of Nephrology, v.9, n.PROGRAM AND ABSTR. ISSUE, 1998.:153A. Conference: 31st Annual Meeting of the American Society of Nephrology.
136. Livsey, Carolyn V.; Taupenot, Laurent; Mahata, Sushil K.; Mahata, Manjula; O'Connor, Daniel T.. Formation of the catecholamine release-inhibitory peptide catestatin by endogenous proteolytic cleavage of chromogranin A within catecholamine storage vesicles: Determination of cleavage sites by mass spectrometry. Hypertension (Dallas), v.32, n.3, Sept., 1998.:603. Conference: 52nd Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research.
137. Miller, Lucy M.; Tyrell, Elizabeth A.; Kailasam, Mala T.; Parmer, Robert J.; Gabbai, Francis B.; O'Connor, Daniel T.. Early alteration in glomerular response to amino acids in humans at genetic risk of essential hypertension. Journal of the American Society of Nephrology, v.9, PROGRAM AND ABSTR. ISSUE, Sept., 1998.:327A. Presented at the 31st Annual Meeting of the American Society of Nephrology. Hypertension (Dallas), v.32, n.3, Sept., 1998.:602. Conference: 52nd Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research.
138. Taupenot, L.; Mahata, M.; Mahata, S. K.; O'Connor, DT. Pituitary adenylyl cyclase-activating polypeptide (PACAP) elicits dual desensitizing and extended effects on the activation of catecholamine (CA) secretion and chromogranin A (CgA) transcription in PC12 cells. Molecular Biology of the Cell, v.9, n.SUPPL., Nov., 1998.:484A. Conference: 38th Annual Meeting of the American Society for Cell Biology
139. Wright, Fred A.; O'Connor, Daniel T.; Yoneda, Lisa U.; Kutey, Greg; Roberts, Elizabeth; Berry, Charles; Weber, James; Timberlake, David; Schlager, Gunther.
A genome scan for blood pressure loci in mice. Hypertension (Dallas), v.32, n.3, Sept., 1998.:594. Conference: 52nd Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research.
1999 140. Kailasam, Mala T.; O'Connor, Daniel T.; Ward, Harry J.; Wilson, Alexander F.;
Parmer, Robert J. Evidence for heritability of renal microalbumin excretion in essential hypertension. Journal of the American Society of Nephrology, v.10, n.PROGRAM AND ABSTR. ISSUE, Sept., 1999.:366A. Conference: 32nd Annual Meeting of the American Society of Nephrology.
O'Connor, Daniel T.
42
141. Parmer, Robert J.; Song, Qing; Kailasam, Mala T.; O'Connor, Daniel T.; Chao, Julie; Chao, Lee. Renal kallikrein excretion is associated with allelic variation in the human tissue kallikrein promoter on chromosome 19q in families with essential hypertension. Journal of the American Society of Nephrology, v.10, n.PROGRAM AND ABSTR. ISSUE, Sept., 1999.:368A. Conference: 32nd Annual Meeting of the American Society of Nephrology.
2000 142. Rana, B.; Mills, P.; Ziegler, M.; Dimsdale, J.; O'Connor, D.; Parmer, R.; Insel, P.
International Society of Hypertension. (18th Scientific Meeting of the International Society of Hypertension Chicago, Illinois, USA August 20-24, 2000). A search for polymorphisms associating with hypertension in the dopamine 1 receptor locus coding region. In: Journal of Hypertension 2000. 18 (Suppl. 4): S180.
143. Rao, Fangwen; Keiser, Harry R.; O’Connor, Daniel T. (33rd Annual Meeting of the American Society of Nephrology and the 2000 Renal Week Toronto, Ontario, Canada. October 10-16, 2000). Malignant and benign pheochromocytoma: Chromaffin granule transmitter secretion and the response to chemotherapy. In: Journal of the American Society of Nephrology, September, 2000. 11 (Program and Abstract Issue): 353A.
144. Ciraku, Ilirana; Kailasam, Mala T.; O’Connor, Daniel T.; Parmer, Robert J. (33rd Annual Meeting of the American Society of Nephrology and the 2000 Renal Week, Toronto, Ontario, Canada. October 10-16, 2000). Renal aldosterone excretion predicts early renal injury in human essential hypertension. In: Journal of the American Society of Nephrology September, 2000. 11 (Program and Abstract Issue): 345A.
2001 145. P Mahboubi, MP Printz, SK Mahata, NR Mahapatra, RO Stuart, DT O’Connor.
The neuroendocrine transcriptome: early, global changes in adrenal gene expression in rodent genetic hypertension. Presented at Amer Heart Assn Council for High Blood Pressure Research, 55th annual meeting, Chicago, September 22-5, 2001. In: Hypertension, 38(3): 496, 2001.
146. NR Mahapatra, M Mahata, SK Mahata, DT O’Connor. Catecholamine storage vesicles: a dynamic cellular pool of calcium during exocytotic secretion? Quantitation of vesicular calcium concentration in living cells by expression of a novel targeted chromogranin A/aequorin (photoprotein) chimera. Presented at Amer Heart Assn Council for High Blood Pressure Research, 55th annual meeting, Chicago, September 22-5, 2001. In: Hypertension, 38(3): 521, 2001.
147. SK Mahata, NR Mahapatra, M Mahata, TC Wang, DT O’Connor. Stimulus-transcription coupling during sympathetic outflow: a novel transgenic promoter/photoprotein approach. Presented at Amer Heart Assn Council for High Blood Pressure Research, 55th annual meeting, Chicago, September 22-5, 2001. In: Hypertension, 38(3): 508, 2001.
148. M Mahata, NR Mahapatra, DT O’Connor, SK Mahata. Novel, potent effects of the gastrointestinal peptide secretin to stimulate catecholamine and catecholamine secretory vesicle protein gene expression in chromaffin cells. Presented at Amer Heart Assn Council for High Blood Pressure Research, 55th annual meeting, Chicago, September 22-5, 2001. In: Hypertension, 38(3): 508, 2001.
149. L Taupenot, KL Harper, NR Mahapatra, DT O’Connor. Intracellular protein trafficking into catecholamine storage vesicles: novel chimeric photoproteins visualized by deconvolution fluorescence microscopy. Presented at Amer Heart
O'Connor, Daniel T.
43 43
Assn Council for High Blood Pressure Research, 55th annual meeting, Chicago, September 22-5, 2001. In: Hypertension, 38(3): 508, 2001.
150. DT O’Connor, M Kailasam, BP Kennedy, MG Ziegler, N Yanaihara, RJ Parmer. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. Presented at Amer Soc Nephrol/ ISN World Congress of Nephrology, 2001 annual meeting, San Francisco, October 10-17, 2001. In: Journal of the American Society of Nephrology September, 2001. 12 (Program and Abstract Issue): 488A.
151. PE Cadman, F Rao, SK Mahata, DT O’Connor. The dysglycemic hormone pancreastatin is active in humans in vivo. Presented at Amer Soc Nephrol/ ISN World Congress of Nephrology 2001 annual meeting, San Francisco, October 10-17, 2001. In: Journal of the American Society of Nephrology September, 2001. 12 (Program and Abstract Issue): 480A.
152. T Shiina; BK Rana; MG Ziegler; DT O’Connor; PA Insel. Identification and characterization of a novel 5’UTR SNP in the human dopamine recepor D1 gene. Presented at the Scientific Sessions 2001 of the American Heart Association Anaheim, CA, USA November 11-14, 2001. In: Circulation October 23, 2001. 104 (17 Supplement): II.145.
153. Jiang, Q.; Taupenot, L.; Mahata, S. K.; Mahata, M.; O'Connor, D. T.; Miles, L. A.; Parmer, R. J.. A novel mechanism for the regulation of catecholamine release: Processing of chromogranin A (CgA) by plasmin. Presented at Amer Soc Nephrol/ ISN World Congress of Nephrology, 2001 annual meeting, San Francisco, October 10-17, 2001. In: Journal of the American Society of Nephrology. 12(Program and Abstract Issue). September, 2001. 569A.
2002 154. L. Taupenot, K. Harper, NR Mahapatra, RJ Parmer, S.K Mahata, DT O’Connor.
Intracellular Protein Trafficking into Catecholamine Storage Vesicles: Identification of a Novel Sorting Determinant in the Secretory Protein Chromogranin A. Presented at Amer Heart Assn Council for High Blood Pressure Research, 56th annual meeting, Orlando, Florida, September 25-28, 2002. In: Hypertension, 40(3): 408, 2002.
155. SK Mahata, NR Mahapatra, M. Mahata, TC Wang, DT O’Connor. Chromogranin A: A Nexus of Nicotinic Signaling to Catecholamine Secretion and Gene Transcription In Viivo. Presented at Amer Heart Assn Council for High Blood Pressure Research, 56th annual meeting, Orlando, Florida, September 25-28, 2002. In: Hypertension, 40(3): 409, 2002.
156. M. Mahata, NR Mahapatra, DT O’Connor, SK Mahata. Secretin Signaling to Catecholamine Secretion and Catecholamine Secretory Vesicle Protein Gene Transcription in Chromaffin Cells. Presented at Amer Heart Assn Council for High Blood Pressure Research, 56th annual meeting, Orlando, Florida, September 25-28, 2002. In: Hypertension, 40(3): 409, 2002.
157. NR Mahapatra, M. Mahata, DT O’Connor, SK Mahata. Novel Cocaine effects on Catecholamine Secretion: Signaling and Interaction with Neuronal Nicotinic-Cholinergic Receptor. Presented at Amer Heart Assn Council for High Blood Pressure Research, 56th annual meeting, Orlando, Florida, September 25-28, 2002. In: Hypertension, 40(3): 409, 2002.
158. F. Rao, PE Cadman, G. Zhang, DT O’Connor. Heredity and Autonomic control of the circulation in Humans: Quantification by Non-Invasive Studiies in Twins. Presented at Amer Heart Assn Council for High Blood Pressure Research, 56th annual meeting, Orlando, Florida, September 25-28, 2002. In: Hypertension, 40(3): 4024, 2002.
O'Connor, Daniel T.
44
2003 159. Mahapatra, Nitish R.; Mahata, Manjula; O'Connor, Daniel T.; Mahata, Sushil K.
Secretin activation of chromogranin A gene transcription: identification of the signaling pathways in cis and in trans. FASEB, 2003. FASEB Journal. 17(4-5):851.12, March 2003.
160. Mahata, Sushil K.; Mahapatra, Nitish R; Mahata, Manjula; O'Connor, Daniel T. Cocaine-catestatin (chromogranin A344-364) co-actions: inhibition of nicotinic-cholinergic stimulation of catecholamine secretion and gene transcription. FASEB, 2003. FASEB Journal. 17(4-5):851.8, March 2003.
161. Mahboubi, Payam; Fries, Ryan S.; Printz, Morton P.; Mahata, Sushil K.; Mahapatra, Nitish R.; Stuart, Robert O.; Schmid-Schonbein, Geert W.; O'Connor, Daniel T. The neuroendocrine transcriptome: early, global changes in adrenal gene expression in rodent genetic hypertension. FASEB, 2003. FASEB Journal. 17(4-5):659.3, March 2003.
162. Tang, Chih-Min; Zheng, Bin; O'Connor, Daniel T; Wiley, James S.; Farquhar, Marilyn G.; Insel, Paul A. Identification of single nucleotide polymorphisms in RGS-PX, novel proteins that function as negative regulators for heterotrimeric GTP-binding proteins (G proteins). FASEB, 2003. FASEB Journal. 17(4-5):145.7, March 2003.
163. Chandran, Rubin; Rao, Fangwen; Cadman, Peter E.; Chen, Alice Y.; Nguyen, Kathy; Bolotnikova, Anna; Zhang, Guangfa; Rana, Brinda K.; Insel, Paul A.; Schork, Nicholas A.; O'Connor, Daniel T. Human pressor responses: Heritability estimations in twins, and genotypic associations at adrenergic and renin/angiotensin loci. Amer Soc Hypetension, 2003. American Journal of Hypertension. 16(5 Part 2):80A, May 2003.
164. Lee, Jean C.; Taylor, Carolyn V.; Gaucher, Sara P.; Toneff, Thomas; Taupenot, Laurent; Yasothornsrikul, Sukkid; Mahata, Sushil K.; Sei, Catherine; Parmer, Robert J.; Neveu, John M.; Lane, William S.; Gibson, Bradford W.; O'Connor, Daniel T.; Hook, Vivian Y. H. Primary sequence characterization of catestatin intermediates and peptides defines proteolytic cleavage sites utilized for converting chromogranin A into active catestatin secreted from neuroendocrine chromaffin cells. Molecular & Cellular Proteomics. 2(7 Supplement):S54, July 2003.
165. Wen, G.; Mahata, S. K.; Cadman, P.; Mahata, M.; Ghosh, S.; Mahapatra, N. R.; Rao, F.; Stridsberg, M.; Smith, D. W.; Mahboubi, P.; O'Connor, D. T.; Hamilton, B. A. Human chromogranin A (CHGA): Discovery of both frequent and rare functional polymorphisms at a locus governing catecholamine storage and release. Amer Soc Hum Genet, 2003. American Journal of Human Genetics. 73(5):393, November 2003.
2004 166. Ho, H.; Hall, S. D.; Flockhart, D. A.; Li, L.; Skaar, T.; Cadman, P.;
O'Connor, D. T. The association between CYP3A5 genotype and antihypertensive response. ASCPT, 2004. Clinical Pharmacology & Therapeutics. 75(2):P62, February 2004.
167. Zhang, Lian; Rao, Fangwen; King, Danuta; Chandran, Rubin; Wessel, Jennifer; Rana, Brinda K.; Kennedy, Brian P.; Zhang, Guangfa; Ziegler, Michael G.; Schork, Nicholas J.; O'Connor, Daniel T. Autonomic nervous system activity (baroreflex sensitivity): Prediction by polymorphism at the tyrosine hydroxylase (TH) locus,
O'Connor, Daniel T.
45 45
the rate-limiting enzyme in catecholamine biosynthesis. Amer Soc Hypertension, 2004. American Journal of Hypertension. 17(5, Part 2):80A, May 2004.
168. Rao, Fangwen; King, Danuta; Wessel, Jennifer; Schork, Nicholas J.; O'Connor, Daniel T. Beta-adrenergic control of human heart rate variability (HRV): Prediction by multiple single nucleotide polymorphisms (SNPS) at the beta-2 (ADRB2) though not the beta-1 (ADRB1) adrenergic receptor genetic loci. Amer Soc Hypertension, 2004. American Journal of Hypertension. 17(5, Part 2):79A-80A, May 2004.
2005. 169. King, Danuta; Etzel, Jason; Chopra, Shagun; Smith, Joshua;
Cadman, Peter E.; Rao, Fangwen; Funk, Stephen D.; Rana, Brinda K; Schork, Nicholas J.; Insel, Paul A.; and O’Connor, Daniel T. Human response to 2-adrenergic agonist stimulation studied in an isolated vascular bed in vivo: biphasic influence of dose, age, gender, and receptor genotype. ASCPT 2005. Clinical Pharmacology and Therapeutics 2005. Vol 77, Number 2: P5, February 2005.
170. Le Corre, Pascal; Parmer, Robert; Kailasam, Mala; Kennedy, Brian; Skaar, Todd; Ho, Herbert; Leverge, Roger; Smith, Douglas; Ziegler, Michael; Insel, Paul; Schork, Nicholas; Flockhart, David; and O'Connor, Daniel T. Human sympathetic activation by -adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism. ASCPT 2005. Clinical Pharmacology and Therapeutics 2005. Vol 77, Number 2: P6, February 2005.
171. Rao, Fangwen; Wen, Gen; Mahata, Sushil; Kennedy, Brian; Stridsberg, Mats; Abel, Kenneth; Smith, Douglas; Eskin, Eleazar; Schork, Nicholas; Hamilton, Bruce; Ziegler, Michael; and O’Connor, Daniel T. The Catecholamine Release Inhibitory Peptide Catestatin (Chromogranin A [CHGA]352-372): A Naturally Occurring Amino Acid Variant (Gly364Ser) Causes Profound Alterations In Human Autonomic Activity. ASCPT 2005. Clinical Pharmacology and Therapeutics 2005. Vol 77, Number 2: P6, February 2005.
172. Zhang, Lian; Rao, Fangwen; Wessel, Jennifer; Kennedy, Brian; Rana, Brinda; Taupenot, Laurent, Lillie, Elizabeth O., Cockburn, Myles; Schork, Nicholas J.; Ziegler, Michael G.; and O’Connor, Daniel T. Functional allelic heterogeneity and pleiotropy of a repeat polymorphism in tyrosine hydroxylase: Prediction of catecholamines and response to stress in twins. ASCPT 2005. Clinical Pharmacology and Therapeutics 2005. Vol 77, Number 2: P6, February 2005.
173. Mahata, Sushil; Mahata, Manjula; Wen, Gen; Wong, William; Mahapatra, Nitish; Hamilton, Bruce; and O’Connor, Daniel T. The Catecholamine Release-Inhibitory “Catestatin” Fragment of Chromogranin A: Naturally Occurring Human Variants with Different Potencies for Multiple Chromaffin Cell Nicotinic Cholinergic Responses. ASCPT 2005. Clinical Pharmacology and Therapeutics 2005. Vol 77, Number 2: P6, February 2005.
174. Etzel, Jason; Rana, Brinda; Wen, Gen; Parmer, Robert; Schork, Nicholas; O’Connor, Daniel T. Genetic Variation at the Human
O'Connor, Daniel T.
46
α2B-Adrenergic Receptor Locus: Role in Blood Pressure Variation and Yohimbine Response. ASCPT 2005. Clinical Pharmacology and Therapeutics 2005. Vol 77, Number 2: P7, February 2005.
B. UNPUBLISHED MATERIAL. 1977 1. O'Connor DT, Weismann M, Fierer J: Hypocomplementemia and
thrombocytopenia in Staph. aureus endocarditis. Presented, Am Soc Microbiol. 1977.
1978 2. O'Connor DT, Stone RA, Preston RA, Mitas JA, Wall J: Race and hypertension:
etiologic differences and response to therapy. Presented, National Med Assoc, 1978.
1981 3. O'Connor DT, Frigon RP, Sokoloff RL: Human catecholamine storage vesicle
proteins. Presented, Hypertension SCOR National Meeting, 1981. 4. Insel PA, Motulsky HJ, O'Connor DT, Snavely MD: Changes in adrenergic
receptors in experimental and human hypertension. Presented, Hypertension SCOR National Meeting, 1981.
1982 5. O'Connor DT, Frigon RP: Chromogranin A, a new probe of sympathoadrenal
function: Quantification by radioimmunoassay. Presented, Am Heart Assoc Council for High Blood Pressure Research, 1982.
1983 6. O'Connor DT, Burton D, Deftos LJ: Human chromogranin A: detection by
immunohistology in diverse polypeptide hormone producing tumors. Presented, Endocrine Society, 1983.
7. See 1982 #5 in this section 1984 8. O'Connor DT, Bernstein KN: Human chromogranin A, the major catecholamine
storage vesicle soluble protein: purification and characterization from CSV of pheochromocytoma, quantitation by radioimmunoassay, and evaluation in plasma as an index of sympathoadrenal activity in normal and hypertensive man. Presented, Symposium on Neuropeptides/Blood Pressure Control, Heidelberg, 1984; International symposium on Molecular Biology of Peripheral Catecholamine Storing Tissues, Colmar, France, 1984; International Society of Hypertension, Switzerland, 1984; Am Heart Association Council for High Blood Pressure Research, 1984.
9. O'Connor DT, Deftos LJ: Chromogranin A: Ubiquitous production by normal and neoplastic peptide producing endocrine tissues, revealed by radioimmunoassay and immunohistology. Presented, International symposium on Molecular Biology of Peripheral Catecholamine Storing Tissues, Colmar, France, 1984.
1985 10. Mezger MS, O'Connor DT: Plasma chromogranin A in subjects with renal
failure: elevations from both degree of renal insufficiency and secondary hyperparathyriodism. Presented, XXII Congress of EDTA/European Renal Association, 1985.
O'Connor, Daniel T.
47 47
11. Deftos LJ, O'Connor DT, Carney DN, Linnoila RI, Gazdar AF: Chromogranin A is expressed in cell lines from small cell lung carcinomas having neuroendocrine properties. Presented, Endocrine Soc, 1985.
12. Deftos LJ, O'Connor DT: Chromogranin A is co-secreted with bone-active peptides and other hormones in humans. Submitted, Am Soc for Bone and Mineral Research, 1985.
13. Kitt CA, Walker LC, Struble RG, Price DL, Johss TH, Wainer BH, O'Connor DT: Distribution of monoamines in monkey hippocampus. Presented, Soc. for Neurosci, 1985.
14. Struble RG, Powers RE, Casanova MF, Kitt CA, O'Connor DT, Price DL: Multiple transmitter-specific markers in senile plaques in Alzheimer's Disease. Submitted, Soc for Neurosci, 1985.
15. Parmer RJ, O'Connor DT: Enkephalins in pheochromocytoma: RIA and chromatographic identification, chromaffin granule localization, and precursor characterization. Presented, 2nd annual Marion Hypertension Research Clinical Fellowship Program, 1985.
1986 16. Deftos LJ, Murray S, O'Connor DT, Delegeane AM, Mellon P: A cloned
chromogranin A cDNA detects a 2.3 Kb mRNA in diverse neuroendocrine tissues. Submitted, Endocrine Society, 1986.
17. O'Connor DT, Deftos LJ (spon: SJ Manolagas): Endocrine neoplasia secrete chromogranin A along with their characteristic resident peptide hormones. Submitted, Endocrine Society, 1986 (not presented).
18. Jengeleski CA, Powers RE, O'Connor DT, Price DL: Noradrenergic innervation of the human pineal gland in aging and Alzheimer's Disease. Submitted, Soc for Neurosci, 1986.
19. O'Connor DT, Deftos LJ: Endocrine neoplasia secrete chromogranin A along with their characteristic resident peptide hormones. Presented, NY Acad Sci Conference on the Cellular and Molecular Biology of Hormone and Neurotransmitter Containing Secretory Vesicles, 1986.
20. O'Connor DT, Parmer RJ, Serck-Hanssen G, Deftos LJ, Murray S, Burton D, Delegeane A, Mellon P: Chromogranin A: studies of its secretion, size forms, and molecular biology. Presented, NY Acad Sci Conference on the Cellular and Molecular Biology of Hormone and Neurotransmitter Containing Secretory Vesicles, 1986.
1987 21. Parmer RJ, Handa M, O'Connor DT: Detection of putative chromogranin clones
from a rat adrenal chromaffin cell cDNA library. Presented, Am Soc Hypertension, 1987.
1988 22. Stoddard S, O'Connor DT, Tyce GM, Yaksh TL, Carmichael S: The secretion of
catecholamines, chromogranin A, and neuropeptide Y from the feline adrenal medulla in situ. Presented, Am Assoc Anatomists, 1988.
23. Nanes MS, O'Connor DT, Marx SJ; Chromogranin A in primary hyperparathyroidism. Presented, Endocrine Society, 1988.
24. Bakhit C, Koda L, Benoit R, Randolph L, O'Connor DT, Bloom FE: Effects of cysteiamine on catecholamines and somatostatin-14 in rat brain.
25. O'Connor DT, Parmer RJ, Koop AH, Wu HJ, Gill BM: Chromaffin cell secretory proteins: molecular biological approaches to their structure and function. Presented, 9th Annual UCSD Neurosciences Information Exchange, 1988.
1989 26. Rogers PJ, Tyce GM, Weinshilboum RM, O'Connor DT, Bove AA:
Catecholamine metabolic pathways and exercise training: plasma and urine
O'Connor, Daniel T.
48
catecholamines, metabolic enzymes, and chromogranin A. Presented, Am. Coll. Cardiol., 1989.
1990 27. To BBC, Ito MK, O'Connor DT: Comparative pharmacokinetics of transdermal
clonidine: the effects of dermal pretreatment with hydrocortisone cream or magnesium-aluminum hydroxide suspension. Presented at Western states conference for pharmacy residents, fellows and preceptors, 1990.
28. Shults CW, Goetz C, Klawans HL, Carvey PM, Watts RL, Bakay RL, U HS, Gage FH, O'Connor DT: Transplantation of the adrenal medulla to the caudate in Parkinsonian patients does not cause an increase in ventricular fluid chromogranin A. Presented, Am. Acad. Neurol., 1990.
29. Gratzl M, Lahr G, Heiss C, Mayerhofer C, Schilling K, Parmer RJ, Pilgrim C, O'Connor DT: Chromogranin A in the olfactory system of the rat. Presented, Society for Neuroscience, 1990.
30. Wand GS, O'Connor DT, Takiyyuddin MA, Levine MA: A proposed role for chromogranin A as a glucocorticoid-responsive autocrine inhibitor of ACTH secretion. Presented, Endocrine Society, 1990.
31. Blind E, Schmidt-Gayk H, Raue F, Ziegler R, O'Connor DT: Chromogranin A in medullary thyroid carcinoma. American Society for Bone and Mineral Research, 1990.
1991 32. O'Connor DT. Chromogranin A: from gene to organism. International
Symposium on Chromaffin Cell Biology, Marburg, Germany, August, 1991. 1992 33. O'Connor DT: The chromogranins: diagnostic value in hypertension and
functional implications for catecholamine storage and release. Presented (plenary lecture), ASH, May, 1992.
